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1. INTRODUCTION 
1.1 SOLID ORAL DOSAGE FORMS 1 
  Oral solid dosage forms such as tablets and hard gelatin capsules, which have 
been in existence since 19th century, remain the most frequently used dosage forms. Oral 
route of delivery is a route that the patient understands and accepts. For the manufacturer 
solid oral dosage forms offer many advantages: they utilize cheap technology, are 
generally the most stable forms of drugs, are compact and their appearance can be 
modified to create brand identification. 
  Tablets and capsules are very versatile. When formulating any pharmaceutical 
dosage form, it is important to remember that there is equilibrium between the 
bioavailability of the product, its chemical and physical stability and the technical 
feasibility of producing it. 
Stability 
                                                     
                                                
 
                                            Bioavailability             Technical feasibility 
 
  Any change made to a formulation in an attempt to optimize one of these 
properties is likely to have an effect on the other two parameters, which must be 
considered. This is especially true of immediate-release solid dosage forms. Many of the 
properties required to optimize the bioavailability through rapid disintegration and 
dissolution of the active constituent, for example small particle size must be balanced with 
the manufacturability, where the fluidity and compatibility of a powder will often be 
enhanced by an increase in particle size.  Tablets and hard gelatin capsules form the vast 
majority of solid dosage forms on the market. While the actual processes involved of 
filling capsules and compressing tablets differ, the preparations of the powders to be 
processed are, in many cases, very similar. 
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 1.2 TYPES OF SOLID DOSAGE FORMS 1 
  There are many different types of tablets which can be designed to fulfill 
specific therapeutic needs. 
Table 1: Types of Solid Dosage Forms 
 
Formulation type 
  
Description 
 
Immediate release 
tablets 
 
The dosage form is designed to release the drug substance 
immediately after ingestion. 
 
Chewable tablets 
 
Strong, hard tablets to give good mouth feel. 
 
Lozenges 
 
Strong, slowly dissolving tablets for local delivery to mouth or 
throat. Often prepared by a candy molding process. 
 
 Buccal tablets 
 
Tablets designed to be placed in buccal cavity of mouth for rapid 
action. 
 
Effervescent 
tablets 
 
Taken in water, the tablet forms an effervescent, often pleasant-
tasting drink. 
 
Dispersible tablets 
 
Tablets taken in water, the tablet forms a suspension for ease of 
swallowing. 
 
Soluble tablets 
 
Tablets taken in water, the tablet forms a solution for ease of 
swallowing. 
 
Hard gelatin 
capsules 
 
Two-piece capsule shells, which can be filled with powders, pellets, 
semisolids or liquids. 
 
Soft gelatin 
capsules 
 
One-piece capsules containing a liquid or semisolid fill. 
 
Pastilles 
 
Intended to dissolve in mouth slowly for the treatment of local 
infections. Usually composed of a base containing gelatin and 
glycerin. 
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1.3 Advantages of solid oral dosage forms 2 
 They are unit dosage forms and offer the greatest capabilities of all oral dosage forms 
 for the greatest dose precision and least content variability. 
 Low cost among all dosage forms. 
 They are lightest and most compact dosage forms. 
 They are easiest and cheapest to package and ship. 
 Product identification requires no additional processing steps when employing an 
 embossed or monogrammed punch face. 
 Easy large scale production. 
 They have the best combined properties of chemical, mechanical and microbiological 
 stability among all dosage forms. 
 Drugs with bitter taste, objectionable odour, sensitivity towards oxygen or hygroscopic 
 nature may require encapsulation/entrapment prior to compression or coating of tablets 
 is required. In such cases, the capsule could be prepared. 
 
1.4 Disadvantages  
 Some drugs having resistance for compression into dense compacts owing to their 
 amorphous nature or flocculent and low density properties. 
 Drugs with bitter taste, objectionable odour, sensitivity towards oxygen or hygroscopic 
 nature may require encapsulation or coating of tablets. 
 Elderly, ill and children could have the problem in swallowing the tablets. 
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 Fig 1: Various Granulation Techniques 
 
1.5 PROCESS INVOLVED IN MANUFACTURING OF ORAL SOLID  DOSAGE 
 FORMS 3 
                   Tablet formulations have been prepared by one of two methods:  
1.  Direct compression 
2.  Granulation. 
 
1.5.1 DIRECT COMPRESSION  
  Direct compression is the term used to define the process where powder blends 
of the drug substance and excipients are compressed on a tablet machine. There is no 
mechanical treatment of the powder apart from a mixing process. It was only used for 
inorganic materials such as potassium bromide. Today, within the pharmaceutical industry, 
the term is used for tablet manufacture that does not involve the pre-treatment of the drug 
substance apart from blending with excipients. 
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1.5.2 Advantages  
 Simplicity and subsequent economy. 
 The omission of a drying step results in lower energy consumption. 
 No need of granulators, driers. 
 Savings in labour cost as well as time. 
 Stability of certain drugs can be improved by the elimination of a wetting and drying 
 process when formulating drugs that are thermolabile or moisture sensitive.  
 
1.5.3 Disadvantages  
 It cannot be used for all drug substances. 
 The technique depends on the major components of the formulation having  appropriate 
 flow and compaction properties. 
 Low-dose drugs by direct compression are related to achieving and maintaining a 
 homogeneous mix. 
 
1.5.4. GRANULATION4 
  Granulation is the most widely used technique to prepare powders for 
compaction. A number of methods can be used to achieve the agglomeration.  
 Granulation is classified as 
 Wet granulation - where a liquid is used to aid the agglomeration process. 
 Dry granulation - where no liquid is used. 
  The purpose of granulating is to transform the powdered starting material into 
granules that will run smoothly on a tablet machine. The granulation process usually 
involves the addition of a polymeric binder that sticks the individual particles together. 
The polymers used as binders are usually hydrophilic in nature. This can have a beneficial 
effect on the dissolution of hydrophobic drugs. During the granulation process, a film of 
hydrophilic polymer will form over the surface of hydrophobic drug particles, which will 
aid wetting.  
 
1.5.5 WET GRANULATION 
  Wet granulation is the most commonly used method in tablet manufacture. 
These methods involve the addition of a liquid usually a polymeric binder to the powdered 
starting materials, and a form of agitation to promote agglomeration followed by a drying 
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process. In most cases, the liquid used is water, although in certain circumstances organic 
solvents such as ethanol or ethanol/water mixtures are used. Non aqueous granulation will 
be considered when the active substance is particularly unstable in the presence of water, 
when water will not wet the powder or possibly if the drug substance forms a significant 
portion of the granulate and demonstrates extreme solubility in aqueous media and control 
of the granulation process becomes difficult due to the occurrence of significant 
dissolution.  
  There are a number of approaches to wet granulation used in the 
Pharmaceutical industry, they all share the following basic principles 
 
 Dry mixing 
  The starting materials are mixed together. Prior to mixing, the ingredients may 
be deagglomerated by a milling or sieving process. If the granulate has a low drug content, 
the active substance may be premixed with one of the ingredients prior to being added to 
the granulation vessel to ensure good content uniformity. 
 
 Addition of granulating liquid 
  The granulating fluid is added to the dry ingredients and mixed to form a wet 
mass. The mixing of the fluid with the dry ingredients leads to agglomeration of the 
powder. This agglomeration can be controlled by altering the amount of fluid added, the 
intensity of the mixing and the duration of the mixing. Depending on the state of 
agglomeration achieved, this stage may be followed by a wet sieving process to break up 
the larger agglomerates. 
 
 Drying 
  The fluid is removed by drying process. 
 
 Milling 
  The dried granulate undergoes a sieving or milling operation to obtain the 
desired particle size distribution. 
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1.5.6 DRY GRANULATION 5 
  Dry granulation involves the aggregation of particles by high pressure to form 
bonds between particles by virtue of their close proximity. Two approaches to dry 
granulation are used in the pharmaceutical industry 
 Slugging  
 Roller compaction. 
 
 Slugging 
  Granulation by slugging is the manufacture of large compacts by direct 
compression. The slugs produced are larger than tablets and are often poorly formed 
tablets exhibiting cracking and lamination. As with tablets, it may be necessary to add a 
lubricant to prevent the compacts sticking to the punches and dies. The compressed 
material is broken up and sieved to form granules of the appropriate size. The granules are 
then blended with disintegrant, lubricant and compressed on a normal tablet punching 
machine. 
 
 Roller compaction 
  In roller compaction, the powder is compacted by means of pressure rollers. It 
is fed between two cylindrical rollers, rotating in opposite directions. By means of a 
hydraulic ram forcing one of the rollers against the other, machine is capable of exerting 
known fixed pressures on any powdered material that flows between the rollers. Powdered 
material is fed between the rollers by a screw conveyor system. After passing through the 
rollers, the compacted mass resembles a thin wide ribbon that has fallen apart into large 
segments. These are equivalent to the slugs produced by the slugging process. The 
segments are then screened or milled for the production of granules. Roller compaction is 
done by using chilsonator.  
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1.6 CHEWABLE TABLETS6 
  Chewable tablets are tablets that are required to be broken and chewed in-
between the teeth before ingestion. These tablets are given to children who have difficulty 
in swallowing and to the adults who dislike swallowing. Chewable tablets are chewed and 
broken into smaller pieces prior to swallowing and are not to be swallowed intact. In this 
way, the time required for disintegration is reduced and the rate of absorption of the 
medicament may increase. For the preparation of chewable tablets, mannitol is used as the 
base. These tablets should have acceptable taste and flavour. They should disintegrate in a 
short time and produce cool sweet taste. 
 
 Advantages 
 Better bioavailability through bypassing disintegration and perhaps enhancing 
 dissolution. 
  Patient convenience through the elimination of the need of water for swallowing 
 (chewable tablets can be taken at any places even if water is not available). 
 Possible use as a substitute for liquid dosage forms where rapid onset of action is 
 desired. 
 Minimized first pass effect. 
 Improved patient acceptance especially in paediatrics through pleasant taste and 
 product distinctiveness. 
 For both physiological and psychological reasons, children up to the young teens 
 usually have trouble in swallowing tablets and capsules. In such cases, chewable 
 tablets are preferable because of their patient acceptability (palatability) and better 
 stability. 
 Easily accessible for self-medication. 
 Possible to achieve an effective taste masking along with a pleasant mouth feel. 
 
 Disadvantages 
 Extremely bad tasting drugs cannot be formulated as chewable tablets. 
  Drugs that have extremely high dosage levels are difficult to formulate. 
 Chewable tablets are to be sipped slowly for longer period of time (wrong usage 
 such as swallowing like conventional tablets leads to reduced therapeutic efficacy). 
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 Requirements 
 Less grittiness. 
 Creamier mouth feel. 
  Improved overall palatability (Good taste and mouth feel). 
 Acceptable bioavailability and bioactivity. 
 Acceptable stability and quality. 
  Economical formula and process. 
 
1.6.1 FORMULATION TECHNIQUES 7   
 
COATING BY WET GRANULATION 
 Microencapsulation 
  Microencapsulation is a method of coating drug particles or liquid droplets 
with edible polymeric materials, thereby masking the taste and forming relatively free 
flowing microcapsules of 5 – 5000µm size. The most common method for taste masking 
application is phase separation or coacervation technique. The resultant coated granules 
not only mask the taste of a drug but also minimize the physical and chemical 
incompatibility between ingredients. However, this method is more expensive and requires 
specialized equipment and knowledgeable personnel. Coagulable water soluble egg 
albumin is used as coating medium for masking the taste of erythromycin. 
 
 Solid dispersions 
  Bad tasting drugs can be prevented from stimulating the taste buds by 
adsorption onto substrates capable of keeping the drugs adsorbed while in the mouth but 
releasing them eventually in the stomach or gastrointestinal tract. 
 
ADSORBATE FORMATION TECHNIQUES 
 Solvent method 
  The formation of an adsorbate involves dissolving the drug in a solvent, 
mixing the solution with the substrate and evaporating the solvent that leaves the drug 
molecules adsorbed upon the substrate. The variables of the process such as choice of 
solvent, substrate, proportions, mixing conditions, rate of evaporation and temperature 
must be optimized to give the desired product. 
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 Melting method 
  The drugs and a carrier are melted together by heating. The molten mixture is 
then cooled and rapidly solidified in an ice bath with vigorous stirring. The product is then 
pulverized and sized. Heat labile drugs, volatile drugs and drug that decompose on melting 
are unsuitable for this method. The method is simple with low cost and no problem of 
residual solvents as in solvent evaporation method. 
 
 Ion Exchange 
  In this technique, the ion exchange materials acts as a drug carrier that helps in 
binding of drugs into an insoluble polymeric matrix and can effectively mask the problems 
of taste and odour in drugs to be formulated as chewable tablets. 
 
 Spray congealing and spray coating 
  The process of spray congealing involves cooling of melted substances in the 
form of fine particles during their travel from a spray nozzle into the spraying chamber 
held at a temperature below their melting point. If slurry of drug material insoluble in a 
melted mass is spray-congealed, discrete particles of the insoluble material coated with the 
congealed substance is obtained. The process of spray coating involves the spraying of a 
suspension of the drug particles in a solution of the coating material through an atomizer 
into a high-velocity stream of warm air. The coarse droplets delivered by the atomizer 
consist of drug particles enveloped by coating solution. As the solvent evaporates, the 
coating material encapsulates the drug particle. 
 
 Formation of different salts or derivatives 
  In this, an attempt is made to modify the chemical composition of the drug 
substance itself, to render it less soluble in saliva and thereby less stimulating for the taste 
buds or to obtain a tasteless or less bitter form. 
 
 Use of amino acids and protein hydrolysates 
  By combining amino acids, their salts or a mixture of two, it is possible to 
reduce the bitter taste. The preferred amino acids are sacrosine, alanine, taurine, glutamic 
acid and glycine. 
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 Inclusion complexes  
  In inclusion complex formation, the drug molecule (guest molecule) fits into 
the cavity of a complexing agent (host molecule) forming a stable complex. The complex 
is capable of masking the bitter taste of the drug. The most commonly used complexing 
agent is cyclodextrin. 
 
 Molecular complexes 
  Molecular complex formation involves a drug and a complexing organic 
molecule. In this, masking of bitter taste or odour of drugs is achieved by forming 
complexes that would lower the aqueous solubility of the drug and thus the amount of drug 
in contact with the taste buds. 
 
1.6.2 ORGANOLEPTIC CONSIDERATIONS 6 
 Taste 
  From the perspective of consumer acceptance, taste is almost certainly the 
most important parameter for the evaluation of chewable tablets. Taste is a combination of 
the perceptions of mouth-feel, sweetness and flavour. Taste is a sensory response resulting 
from a stimulation of the taste buds on the tongue. There are four basic types of taste: 
salty, sour, sweet and bitter. Salty or sour taste is derived from substances capable of 
ionizing in solution. 
  Many organic medications exhibit a bitter response even though they may not 
be capable of ionizing in an aqueous medium. Substances incapable of producing a 
sensory stimulation of the taste buds are referred to as bland or tasteless. Sweetness at an 
appropriate level is a necessary background to a flavour. The primary contributors to 
sweetness in a chewable tablet are the drug, natural sweeteners and artificial sweetness 
enhancers that may be incorporated in the formulation. 
 
 Aroma 
  Pleasant smells are generally referred to as aromas.  
            For example:  Orange flavour has an aroma of fresh orange. 
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 Mouth feel 
  Mouth feel is affected by the heat of solution of the soluble components 
(negative heat preferable), smoothness of the combination during chewing and hardness of 
the tablet. These factors are directly and almost entirely related to the active ingredient and 
major excipients. The term mouth feel is related to the type of sensation or touch that a 
tablet produces in the mouth upon chewing. It has nothing to do with chemical stimulation 
of olfactory nerves or taste buds. However, for a formulation to be successful, the overall 
effect in the mouth is important. 
 
 After effects 
  The most common after effect of many compounds is after taste. For example, 
some iron salts have a rusty after taste; saccharin in high amounts tends to leave a bitter 
after taste. Another common after effect is a sensation of numbness of a portion or the 
whole surface of the tongue and mouth. 
 
 Flavouring 
  The term flavour generally refers to a specific combined sensation of taste and 
smell (olfaction). Flavour is imparted in a chewable tablet formulation by the use of 
various synthetic and natural flavouring compounds. Flavours are available as either 
liquids or spray-dried, free-flowing, fine granules. Liquid flavour compounds can be added 
to dry granules obtained from wet granulation or to dry granulation blends as fine spray. 
Spray-dried flavour granules can also be added directly to dry granules obtained from wet 
granulation or to direct compression blends. 
 
 Colouring 
  For aesthetic appeal and product differentiation, chewable tablets are often 
coloured. Colorants can also be used to mask unappealing natural colour, resulting from 
various raw materials. Colorants can be used for the uniform production of batches if raw 
materials have a slightly different colour. Colorants in chewable tablets are usually chosen 
to match the flavour. Colorants are available as natural pigments and synthetic organic 
dyes. In chewable tablets, the most widely used forms of the colorant are aqueous soluble 
dyes and lakes made from these dyes. 
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 Chewability 
  Acceptability of chewable dosage forms also depends on the chewability of the 
product. Chewability of a chewable dosage form may be defined as effortless chewing of 
the product with no desirable gumminess, stickiness, chalkiness or grittiness, yet coupled 
with a pleasant cooling sensation in the mouth. These properties are imparted by the use of 
excipients that have inherently good mouth feel and chewability characteristics. Excipients 
with such properties include mannitol and blends of mannitol, sorbitol, fructose and 
sucrose. 
 
1.6.3 Evaluation 
  Physical examination 
  Hardness 
  Friability 
 Dosage uniformity 
 Disintegration 
 Assay for drug content 
  Dissolution 
 Consumer acceptance simulation testing 
 
1.6.4 Stability Testing 6  
  Stability testing of dosage forms or drug products is carried out to evaluate 
time dependent changes, if any occurring within the dosage forms. Stability testing may be 
either accelerated or real time under ambient conditions. Accelerated storage conditions 
include high temperatures, high relative humidity and high light intensities. The stability 
testing of chewable tablets would include the following test:  
 Active drug content determination. 
 Changes in physical characteristics of the tablets. 
 Changes in tablet hardness, friability, dissolution rate/extent of dissolution and 
 increase in disintegration time. 
  Moisture content of tablets. 
 Stability of tablet taste-masking system. 
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 1.6.5 Special problems encountered with Chewable Tablets 
  Due to the particular attributes, chewable tablets present several special 
difficulties with respect to the formulation, manufacture, packaging and evaluation. 
 
 Formulation 
  The associated attributes of a pleasant taste with matching colour, smoothness, 
mouth feel and chewability carry with them unusual formulation requirements compared to 
the tablets intended to be swallowed. The challenge of converting usually bad tasting 
(bitter, acidic or chalky) drugs into pharmaceutically elegant, good tasting dosage forms 
requires the application of highly specialized formulation skill. Flavour selection demands 
care in determining whether to mask or enhance the taste of the drug. Additionally, 
flavours should rarely be used singly; rather flavour blends can be used. Colour 
incorporation in chewable tablet formulation may be either by the use of dyes in wet 
granulation or by the use of lakes in direct compression or as additions to wet granulated 
materials after drying. The use of light or pastel colours in low concentration appropriately 
incorporated is critical to the overall appearance and acceptability of the product. 
Formulating for smoothness and mouth feel involves not only judicious excipient selection 
but also careful process development in establishing such parameters such as particle size, 
moisture content and compressional force. The importance of tablet hardness and friability 
cannot be over emphasized; minor changes in these variables may result in significant 
differences in perceived satisfaction during chewing. The tablets must be hard enough for 
machine handling, soft enough to be bitten easily, hard enough to provide acceptable 
consistency, soft enough to be chewed, hard enough not to feel powdery and soft enough 
to be smooth. 
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 Manufacturing 
   The four important aspects of chewable tablet manufacture related to 
the following: 
 Proper incorporation of colouring agent. 
 Assurance of necessary particle size distribution. 
 Maintenance of correct moisture content. 
 Achievement of proper tablet hardness. 
 
  The method and timing for the addition of flavour and colour must be 
determined if wet granulation is being used. Because most flavour substances are volatile, 
they cannot be subjected to elevated temperature. For this reason, they cannot be 
incorporated prior to wet granulation; rather flavours are added in the final blending 
operation of the process. The colour in the form of lake would be incorporated in the same 
step.  
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2. LITERATURE REVIEW 
2.1  Literature Review for Chewable Tablets 
 Swati Jagdale et al.8 formulated the chewable tablets of levimasole to overcome the 
 difficulty in swallowing for paediatric and geriatric patients. Chewable tablets were 
 prepared by using lactose or mannitol along with sodium starch glycolate in varying 
 concentrations. Sodium saccharin and vanilla were used as sweetening agent and 
 flavouring agent respectively. From the disintegration studies, it was observed that the 
 formulation having no or less concentration of sodium starch glycolate shows increase 
 in disintegration time. It was observed that the formulation containing lactose shows  less             
 disintegration time than formulation containing mannitol. 
 Hiroyuki Suzuki et al.9 developed an oral acetaminophen chewable tablets with 
inhibited bitter taste. Various formulations were developed using corn starch/lactose, 
cacao butter and hard fat (Witepsol H-15) as matrix bases and sucrose, cocoa powder and 
Benecoat BMI-40 as corrigents against bitter taste. The bitter taste intensity was evaluated 
using volunteers by comparison of test samples with standard solutions containing quinine 
at various concentrations. As a result the tablets made of Witepsol H-15/Benecoat BMI-
40/sucrose, of Witepsol H-15/cocoa powder/sucrose and of Witepsol H-15/sucrose best 
masked the bitter taste so that they were tolerable enough to chew and swallow. The 
dosage forms masked the bitter taste well and showed good drug release indicating little 
change in bioavailability by masking. 
 Kathiresan K et al.10 formulated the loratadine chewable tablet 5mg to improve the 
patient acceptance in children. In this, five batches of loratidine tablets were formulated 
and evaluated. Various parameters like thickness, weight variation, friability, hardness, 
content uniformity of all formulations were studied. In invitro dissolution study, 
formulation 5 showed comparable release with innovator. Three month stability study of 
formulation 5 showed that there was no significant change in physical parameters, drug 
content and dissolution profile. So this study concluded that formulation 5 containing 
Avicel CE 15 and starch paste showed better characteristics than all other formulations. 
 Michele et al.11 studied the safety of chewable tablets in paediatric age group. 
Various informations on chewable tablets was performed from Jan 1996-Jan 1999 by 
evaluating various factors such as drug formulation, aspiration, choking, airway 
obstruction and foreign body. Additional information was obtained from the Physician’s 
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desk reference, IMS Health National Prescription Audit Plus. The results of this study 
showed that more than 60 chewable tablet formulations are approved for use in United 
States of America. The advantages of chewable tablets include palatability, stability, 
precise dosing, portability and ease of delivery. From the available literature suggests that 
chewable were safe, well tolerated alternative to traditional paediatric drug formulations 
and offer significant advantages in children 2 years of age and older.  
 Hiraku Onishi et al.12 developed acetaminophen chewable tablets with suppressed 
bitterness and improved oral feeling by examination of hard fats as the matrix base and of 
sweetening agents as corrigents. Witepsol H-15, W-35, S-55, E-75, E-85 and Witocan H/ 
Witocan 42/44 were used for improved oral feeling. Sucrose, xylitol, saccharin, saccharin 
sodium, aspartame and sucralose were used as sweetening agents and applied alone or 
with Benecoat BMI-40 or cocoa powder. As a result of this study it was concluded that 
Witocan H tablet with Sc1-B5 is suggested as the best acetaminophen chewable tablet, 
exhibiting suppressed bitterness, low sweetness, improved oral feeling and good drug 
release. 
 Matthew P Millarney et al.13 studied the powder flow compact mechanical 
properties of sucrose and three high-intensity sweeteners used in chewable tablets. 
Sucrose, acesulfame potassium, saccharin sodium and aspartame are common 
pharmaceutical sweeteners used in solid dosage forms. These sweeteners were evaluated 
to determine the particle size, shape and true density. Powder flow, cohesivity and other 
mechanical properties were measured. Among these sweeteners, sucrose and acesulfame 
potassium showed excellent flowability and marginal mechanical property whereas 
saccharin sodium and aspartame demonstrated poor flowability and superior compact 
strength than the other. The study concluded that the sweetener selection should be 
appropriate to the done according the tableting process. 
 
 Barbara Knorr et al.14 made a study on dose selection of montelukast for adults as 
well as children. For adults (above 15 years of age), a 10 mg film coated tablet (FCT) is 
available and for children a 5mg chewable tablet (CT) is available. The adult montelukast 
dose (10-mg FCT) was selected on the basis of classic dose-ranging studies as the lowest 
dose that produces maximal improvement in both measures of airway function and 
patient- reported outcomes in chronic asthma and in the attenuation of exercise-induced 
bronchoconstriction. The strategy used for the paediatric dose selection for montelukast 
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was based on the determination of a CT dose that would provide an overall systemic 
exposure to montelukast in children similar to that in adults who receive a 10-mg FCT 
dose. A 5 mg chewable tablet yielded a comparable single-dose area under the plasma 
concentration-time curve profile to that of the adult 10-mg FCT dose and therefore it was 
selected as the paediatric dose for children aged 6 to 14 years with asthma. Subsequently, 
2 studies of efficacy and tolerability validated the choice of the 5-mg CT dose.  
 Patsalos PN et al.15 compared the efficacy and tolerability of chewable 
carbamazepine to conventional carbamazepine in patiens with epilepsy. Thirty patients 
were studied. Duration of epilepsy was 21-68 years (median 34 years). Conventional and 
chew tablets were given and their serum concentration is measured from time to time. As a 
result of study it was concluded that chew tabs were essentially equivalent to the 
conventional formulation in efficacy and tolerability. After 12 weeks treatment, 19 
patients preferred the chewable formulation. 
 Gary M Landsberg et al.16 studied the effectiveness of fluoxetine chewable tablets 
in the treatment of canine separation anxiety (SA) signs such as excessive salivation, 
inappropriate defecation, vocalization and urination. The study was carried as multi-
center, placebo controlled, double blind, randomized parallel- arm study with 208 client 
owned dogs diagnosed with SA. As a result of this study it was conclude that fluoxetine 
chewable tablets at 1-2mg/kg/day showed some efficacy in improving overall separation 
anxiety severity scores in dogs. Fluoxetine chewable tablets represent a viable therapy for 
a condition that veterinary behaviourists rank as the second most common canine 
behavioural disorder. 
 Thomas J Nolan et al.17 studied the efficacy of an ivermectin/pyrantel pamoate 
chewable formulation against the canine hookworms, uncinaria stenocephala and 
ancylostoma caninum. This combination is for monthly use as a heartworm preventative 
and for treatment and control of canine hookworms. The formulation was found to be 
effective against both species of hook worms in experimentally infected dogs. No adverse 
effects was observed in any dog during the study by this drug combination. 
 
2.2 Literature Review for Ubidecarenone 
 Pushp R Nepal et al.18 formulated solid dispersion of Coenzyme Q10 using 
Poloxamer 407 and Aerosil 200 to enhance the solubility and dissolution of CoQ10. Solid 
dispersion of CoQ10 with poloxamer 407 in weight ratio 1:5 prepared by melting method 
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but it exhibited poor stability. Then solid dispersion of CoQ10, Poloxamer 407 and Aerosil 
200 (colloidal silicon dioxide) in the weight ratio 1:5:6 was formulated which exhibited 
improved stability during one month stability test, also solid dispersion containing Aerosil 
200 showed enhanced drug release as well as dissolution rate of CoQ10. From the study it 
was concluded that solid dispersion formulation of CoQ10 with poloxamer 407 and 
Aerosil 200 possess enhanced solubility and dissolution rate of CoQ10 with good 
flowability and cost effectiveness. 
 Kommuru TR et al.19 formulated a self emulsifying drug delivery systems (SEDDS) 
of Coenzyme Q10 and its bioavailability is compared with powder formulation of CoQ10. 
Four types of SEDDS were prepared using two oils (Myvacet9-45 and Captex-200), two 
emulsifiers (Labrafac CM-10 and Labrasol) and a cosurfactant (lauroglycol). In all the 
formulations the level of CoQ10 was fixed at 5.66% w/w of the vehicle and the 
formulations are evaluated by droplet size analysis and pseudo ternary phase diagrams 
were constructed to find out the efficient self-emulsification region. Then the optimized 
formulation containing Myvacet 9-45 (40%), Labrasol (50%) and lauroglycol (10%) was 
selected and its bioavailability is compared with powder formulation of CoQ10. SEDDS 
shown improved bioavailability than powder formulation. 
 Sun sang kwon et al.20 has done the preparation, characterization of Coenzyme Q10 
loaded Poly (methyl methacrylate) nano particles by a new emulsification process based 
on microfluidization and solvent evaporation method. The mean diameter of nano particles 
was found out by dynamic light scattering and transmission electron microscopy. The size 
of the particles depend upon the surfactants used and the recycling number of the 
microfluidization process. By 1H NMR analysis the drug loading is estimated and it is 
found out to be above 95%.  CoQ10 at its melting point 48°C formed a crystal structure 
within the polymer matrix and it was confirmed by differential scanning calorimetry. From 
the study it was concluded that polymer nanoparticles can be utilized as an effective 
means to stabilize chemically unstable drugs as well as to solubilise poorly soluble drugs. 
 Ankola DD et al.21 formulated potent oral nano particles of CoQ10 to improve its 
bioavailability for the treatment of hypertension. Biodegradable nanoparticulate 
formulations based on poly(lactide-co-gylcolide) (PLGA) were prepared by emulsion 
technique using quaternary ammonium salt didodecyldimethylammonium bromide 
(DMAB) as a stabilizer. The entrapment efficiency and the particle size was studied using 
5- 30% loading (107–110 nm). However, 50% and 75% led to increase in particle size 
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with no appreciable changes in entrapment efficiency. Then the intestinal uptake of 
CoQ10 as a suspension in carboxymethylcellulose (CMC), a commercial formulation and 
the developed nano particulate formulation was studied comparatively. The results shown 
that the developed nanoparticulate formulation had improved efficacy at a 60% lowered 
dose as compared to CoQ10 suspension and superior efficacy than the commercial 
formulation at an equal dose. 
 Effat Sadat et al.22 formulated and evaluated CoQ10 loaded solid lipid nanoparticles 
(SLN) cream and done a comparison study between simple cream of CoQ10, solid lipid 
nanoparticle alone and CoQ10 loaded solid lipid nanoparticles. Solid lipid nanoparticles of 
CoQ10 were formulated using high pressure homogenization method. The best 
formulation of SLN dispersion consisted of 13% lipid (cetyl palmitate or stearic acid), 8% 
surfactant (tween 80) and water. Stability tests, particle size analysis, differential scanning 
calorimetry, transmission electron microscopy and release study were conducted to find 
the best formulation. . In vitro release profiles of CoQ10 from simple cream, SLN alone, 
and CoQ10-loaded SLN cream showed prolonged release for SLNs compared with the 
simple cream, whereas there was no significant difference between SLN alone and SLN in 
cream. In vitro release studies also demonstrated that CoQ10-loaded SLN and SLN cream 
possessed a biphasic release pattern in comparison with simple cream. In vivo skin 
hydration and elasticity studies on 25 volunteers suggested good dermal penetration and 
useful activity of CoQ10 on skin as a hydrant and antiwrinkle cream. 
 Weis M et al.23 has carried out the comparitive study for bioavailability of four oral 
Coenzyme Q10-over trial. The included formulations were: a hard gelatin capsule 
containing 100 mg of CoQ and 400mg of Emcompress. Three soft gelatin capsules 
containing : 100mg of CoQ with 400mg of soy bean oil (Bioquinon); 100mg of CoQ with 
20mg of polysorbate 80, 100mg of lecithin and 280mg of soy bean oil; and 100mg of CoQ 
with 20mg of polysorbate 80 and 380mg of soybean oil respectively. The result suggests 
that the soya bean oil suspension of   CoQ has highest bioavailability. 
 Junya Hatanaka et al.24 studied the physicochemical and pharmacokinetic 
characterization of water soluble Coenzyme Q10 formulations. In this investigation, a 
nano emulsion (NE) and water soluble powder formulations including cyclodextrin-Q10 
(CoQ10-CD) and dry emulsion (DE) were prepared and its physicochemical properties 
were characterized by dynamic light scattering, scanning electron microscopy, powder X-
ray diffractometry and differential scanning calorimetry. Based on the results from 
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physicochemical characterization, CoQ10-loaded NE systems exhibited negatively 
charged and highly stable dispersion with submicron diameter when they were dispersed 
in water. In DE systems, CoQ10 existed mainly as an amorphous form, and this could be 
attributed to the higher solubility and dispersibility as compared to the crystalline form. 
Considering significant increment of both Cmax and AUC of CoQ10, NE methodology 
could be the most effective among all formulations tested for the improvement of oral 
absorption of CoQ10. 
 Pariya Thanatuksorn et al.25 formulated CoQ10 with fats and emulsifiers to 
improve the bioavailability of CoQ10 and it was compared with that of a standard 
commercial product. Five commonly used fats (olive oil, safflower oil, coconut oil, butter 
and cocoa butter) four types of emulsifier (lecithin, monoglycerids, calcium stearoyo-2-
lactate (CSL) and diacetyl tartaric acid esters of monoglycerides and two types of aqueous 
phase (distilled water with or without 8g/100g w/w skim milk). From the results it was 
found that oral bioavailability of the emulsified product was slightly greater than that of as 
standard commercial product.  
 Sarah Molyneux et al.26 studied the concentration response to the Coenzyme Q10 
supplement Q-gel in human volunteers to identify the most effective dose Q-gel for use in 
supplementation studies. In this randomized cross over design, 8 young healthy male 
volunteers involved and they received single doses of 60,150 and 300mg of CoQ10    via  
Q-gel soft gel capsules. Blood samples were collected and analyzed for CoQ10. As a 
result of this study it was concluded that most efficacious single dose of Q gel is 200 mg 
and higher absorption is obtained using multiple smaller capsules. 
 Ullmann U et al.27 has made the comparison of  bioavailability of a new tablet grade 
Coenzyme Q10 formulation(all-Q) with CoQ10 (Q gel) softsules from Tishcon 
corporation and Q-sorb from Nature’s Bounty. Twelve healthy male subjects participated 
in a randomized, three-period cross over bioequivalence study. To compare bioavailability 
various pharmacokinetic parameters such as plasma CoQ10, AUC, Cmax for all three 
formulations were studied. The bioequivalence test concluded that Q-gel and all Q were 
found to be having better bioavailability properties than Q-sorb. At the sametime all-Q and 
Q-gel were bioequivalent, but all-Q can be used in tablets but Q-gel should be used in soft 
gels. 
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 Michael V Miles et al.28 compared the bioavailability of Coenzyme Q10 from the 
over-the-counter supplements which are solubilized and non-solubilized in nature. The 
product A (LiQ-10), B(Q-Nol) and the reference product C (UbiQ gel) were given to nine 
healthy adults in single 180 mg doses of each Coenzyme Q10 formulation at two week 
intervals. ANOVA comparison for maximum plasma concentrations (Cmax), time of 
maximum concentrations (tmax), areas under the concentration (AUC) were done. The 
results of this study showed that LiQ-10 has increased bioequivalence compared to the 
reference product but did not reach statistical significance. Q-Nol has increased 
bioavailability compared to the reference product. 
 Choi CH et al.29 has studied the relative bioavailability of Coenzyme Q10 emulsion 
and three liposome formulations after a single oral administration (60mg/kg) into rats.  
Emulsion was prepared using phospholipon 85G as emulsifier and three liposome 
formulations (neutral, anionic and cationic) were prepared by thin film hydration 
technique using phospholipon 85G, cholesterol and charge carrier lipids. Bioavailability of 
CoQ10 in emulsion was 1.5 to 2.6 fold greater than liposome formulations in terms of 
AUC and tmax was 3h for emulsion while for liposomes it was more than 6h. From the 
study it is suggested that bioavailability is a primary concern in selecting CoQ10 product 
especially when high plasma level is required in treatment of heart failure and parkinson’s 
disease. 
 Karen M Smith et al.30 studied the dose ranging and efficacy study of high dose 
Coenzyme Q10 formulations in huntington’s disease in R6/2 transgenic mouse model. 
CoQ10 resulted in a marked improvement in motor performance and grip strength, with 
reduction in weight loss, brain atrophy, and huntington inclusions in treated R6/2 mice. 
From the study it was demonstrated that high-dose administration of CoQ10 exerts a 
greater therapeutic benefit in a dose dependent manner in R6/2 mice than previously 
reported and suggest that clinical trials using high dose CoQ10 in Huntington Disease 
patients are warranted. 
 Terao K et al.31 studied the enhancement of oral bioavailability of Coenzyme Q10 by 
complexation with cyclodextrin in healthy adults. In this study bioavailability of CoQ10 
with microcrystalline cellulose (CoQ10-MCC) is compared  with cyclodextrin(CoQ10-
CD) in twenty two volunteers. Single dose of 150mg capsule containing 30mg of CoQ10 
were given and plasma levels of CoQ10 were determined by HPLC technique. From this 
study it is concluded that the oral absorption and bioavailability of CoQ10 in healthy adult 
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volunteers could be significantly enhanced by complexation with cyclodextrin, suggesting 
the potential use of cyclodextrin as formulation aid for orally administered CoQ10. 
 Abdel-azim et al.32 has done investigation to compare the bioavailability of three 
Coenzyme Q10 formulations in dogs using an open, randomized, multiple-dose cross over 
design. The formulations included a powder filled capsule (A,control) and two soft gelatin 
formulations (Q gel as water miscible of CoQ10,B and Q-Nol as the water miscible form 
of ubiquinol, the redudced form of CoQ10,C). Blood samples were collected for 72hr and 
plasma CoQ10 concentrations were determined by HPLC. Various parameters like AUC, 
Cmax, Tmax were calculated and compared statistically. From the investigation it was 
concluded that soft gelatin capsules containing water miscible CoQ10 formulations B (Q 
gel) and C(Q-Nol) were superior to powder filled formulations with regard to their 
biopharmaceutical characteristics. 
 Jing Zhang et al.33 studied about the effects of the molecular weight (Mw) and 
concentration of trimethyl chitosan (TMC) on Coenzyme Q10-loaded liposomes coated 
with trimethyl chitosan in selenite induced cataract. Particle size distribution and zeta 
potential was studied by transmission electron microscopy (TEM) and the entrapment 
efficiency was investigated. Then the precorneal residence time was studied in comparison 
with control group. In conclusion, the physical properties and precorneal retention time of 
liposomes could be modified with TMC and ophthalmic instillation of Coenzyme Q10 is 
able to retard selenite-induced cataract formation. 
 Anna Rita Fetoni et al.34 compared the effectiveness of CoQ10 with water soluble 
Coenzyme Q10 formulation (Q-ter) in a guinea pig model in preventing the noise induced 
hearing loss. CoQ10 was given intraperitoneally 1 h before and once daily for 3 days after 
pure tone noise exposure (6 kHz for 1 h at 120 dB SPL). Functional and morphological 
studies were carried out to find out the signs of apoptosis. Treatments decreased active 
caspase 3 expression and the number of apoptotic cells, but animals injected with Q-ter 
showed a greater degree of activity in preventing apoptosis and thus in improving hearing. 
These data confirm that solubility of Coenzyme Q10 improves the ability of CoQ10 in 
preventing oxidative injuries that result from mitochondrial dysfunction. 
 Stephen T Sinatra 35 studied about the Coenzyme Q10 supplementation in the 
management of congestive heart failure. CoQ10 adjunctive therapy results to improve the 
quality of life and decrease in the incidence of cardiac complications in congestive heart 
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failure. But dosing, clinical application, bioavailability and dissolution of CoQ10 should 
be considered and based on that Q10 formulation should be supplemented to the patients. 
 Clifford W Shults et al.36 investigated about the safety and tolerability of high 
dosages of Coenzyme Q10 in 17 patients with Parkinson’s disease. Escalating dosage of 
Coenzyme Q10 -1200,1800, 2400, 3400mg/day  with a stable dosage of vitamin E 1200 
IU/day was given and then plasma levels were noted. It was found that plasma level 
reached plateau at 2400mg /day and did not increase further at the 3000mg/day dosage. 
Thus from the study it was suggested that 2400mg/day is an appropriate highest dosage of 
CoQ10 to be given in Parkinson’s disease. 
 Salvatore Pepe et al.37 made a review on role of Coenzyme Q10 in cardiovascular 
disease and given the following conclusions; 1.There is promising evidence of a beneficial 
effect of CoQ10 when given alone or in addition to standard therapies in hypertension and 
in heart failure, but less extensive evidence in ischemic heart disease. 2. Large scale multi-
centre prospective randomised trials are indicated in all these areas but there are 
difficulties in funding such trials. 3. Presently, due to the notable absence of clinically 
significant side effects and likely therapeutic benefit, CoQ10 can be considered a safe 
adjunct to standard therapies in cardiovascular disease. 
 
2.3 Literature Review for Excipients 
 Arnew Holzer and John Sjogren38 were studied the ability of sodium stearyl 
fumarate to reduce friction and adhesion to the punches and its influence on the tablet 
strength and disintegration time. The effect of lubricant concentration, particle size and 
mixing time was investigated using lactose and sodium chloride as tablet materials. Direct 
comparison of magnesium stearate with sodium stearyl fumarate was made. The friction 
and adhesion during ejection of tablets, disintegration time was studied and compared. As 
a result, it was concluded that Sodium stearyl fumarate was found to be a good alternative 
to magnesium stearate as a lubricant. 
 Rizk S et al.39 investigated the effect of lubricant on compression characteristics and 
drug dissolution rate of scleroglucan hydrophilic matrix. In this Sodium stearyl fumarate 
was compared to magnesium stearate and relationship between an increase in the polymer 
concentration and lubricant on compression behaviour and dissolution rate was studied. As 
a result, it was found that 0.5% of lubricant can influence both the compression ability and 
drug dissolution rate of scleroglucan hydrophilic matrix.  
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 Jayadev Patil et al.40 worked on the formulation, design and evaluation of orally 
disintegrating tablets of loratidine using direct compression process. Loratidine tablets 
were formulated using suitable excipients like Maltodextrin, Mannitol, Micro crystalline 
cellulose, combination of Mannitol with starch, aspartame, croscarmellose sodium, citric 
acid, sodium bicarbonate along with Mint flavour. The tablets were evaluated for weight 
variation, hardness, friability, drug content, wetting time and disintegration time along 
with invitro dissolution. Finally it was concluded that the loratidine tablets formulated 
using commercial grades of excipients like combination of Mannitol with starch and 
Micro crystalline cellulose along with super disintegrants like croscarmellose sodium was 
found to be good. 
  Uday S Rangole et al.41 worked on formulation and invitro evaluation of rapidly 
disintegrating tablets by direct compression technology using hydrochlorthiazide as a 
model drug. Tablets were formulated using different concentration of superdisintegrants 
like croscarmellose sodium and crospovidone. Tablets were evaluated for disintegration 
time, wetting time, hardness, thickness, friability, uniformity of weight and dissolution 
study. As a result, it was found that crospovidone 4% gives disintegration in 16 sec and 
shows 100% drug release within 14 min is selected as the optimized formulation and its 
stability was found to be good for thirty days.    
 Ganesh Mahadev Chaulang et al.42 studied the effect of Crospovidone on physical 
properties and dissolution profile of tablets. From the study it was concluded that 
Crospovidone can be used for better dissolution of poorly soluble drugs like furosemide. 
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3. AIM AND PLAN OF WORK 
Aim 
To formulate Ubidecarenone chewable tablet containing 400mg and to evaluate 
organoleptic characters such as taste and flavour along with in vitro release studies. 
Plan of the work 
 Pre-formulation studies 
 Drug- Excipent compatability studies 
 Assay 
 Water content 
 In process Quality Control Checks for derived properties like Bulk Density, Tapped 
Density, Compressibility Index, Hausner’s Ratio and Angle of Repose for drug and 
blends to be determined. 
 Optimization of concentration of ingredients such as Flavours, Sweeteners, 
Disintegrant, Wetting agent, Glidant and Lubricant. 
 Formulation of Chewable tablets with optimized ingredients. 
 Evaluation of chewable tablets for post compression parameters like Uniformity of 
Weight, Thickness, Hardness, Friability, Disintegration Time, Assay and in vitro drug 
release characteristics to be studied.  
 Palatability test has to be done for the optimized batch. 
 Accelerated Stability Studies of the Ubidecarenone chewable  tablets  packed in 75 cc 
Amber coloured HDPE Bottle with 33 mm PP Child Resistant Cap with Induction 
sealed having 1 g of 6 g / yard cotton as dunnage, and 2 no’s of 1 g Silica gel canister 
as desiccant; shall be determined at 40 ± 2°C / 75 ± 5% RH at one month interval for 
3 months and the following are used as raiders for evaluation while comparing with 
Initial, 
 Appearance 
 Uniformity of weight 
 Thickness and Hardness 
 Disintegration Time 
 Water content  
 Assay 
 Dissolution studies 
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3. MARKETED FORMULATIONS OF UBIDECARENONE 
Table No.2: Marketed formulations of Ubidecarenone 
S.No Brand Name Strength Dosage form Manufacturer 
1 CoQ10 
 
10mg,30mg,50mg, 
100mg,200mg, 
300mg 
 
Soft gels Carlson labs, USA. 
2 Coenzyme  Q10 30mg, 100mg, 200mg, 400mg Soft gels 
Natural factors, 
Canada. 
3 Coenzyme  Q10 50mg Soft gels Roex, USA. 
4 Coenzyme  Q10 Sublingual 30mg, 60mg Tablets 
Source naturals, 
USA. 
5 
CoenzymeQ10 
(emulsified with 
lecithin soya) 
200mg Soft gels 
Douglas 
laboratories, 
USA. 
6 CoQ10 100mg Soft gels Zenith Nutritions, India. 
7 Ubi Q 30mg Soft gels Fourrts India Ltd, India. 
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5. DRUG PROFILE OF UBIDECARENONE43 
Drug name  : Ubidecarenone 
Synonym  : Coenzyme Q10  
CAS NO  : 303-98-0 
Formula  : C59H90O4 
Molecular weight : 863.34  
Physical form : yellow to orange crystalline powder 
Odour  : characteristic  
Taste  : bland taste 
Melting point : 48ºC   
Structure  : 
 
 
Chemical Name : 2,3-Dimethoxy-5-Methyl-6-Decaprenyl benzoquinone 
 
Solubility  :  Practically insoluble in water, soluble in acetone, very slightly  
          soluble in ethanol. 
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 5.1 PHARMACOLOGY 44, 45     
 5.1.1 Pharmacodynamics  
   The primary role of Ubidecarenone is as a vital intermediate of the electron 
transport system in the mitochondria. Adequate amounts of Ubidecarenone are necessary 
for cellular respiration and ATP production. Due to its involvement in ATP synthesis, 
Ubidecarenone affects the function of all cells in the body, making it essential for the 
health of all tissues and organs. Ubidecarenone also functions as an intercellular 
antioxidant at the mitochondrial level, perhaps accounting for its benefit in 
neurodegenerative diseases, male infertility and periodontal disease. 
  
 
Fig 2: Electron Transport Chain 
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Fig 3: Role of Ubidecarenone in Energy Production 
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5.1.2 Pharmacokinetics 46 
 
  ABSORPTION  
 Ubidecarenone is absorbed from the small intestine, passes into the lymphatics, and 
 finally to the blood and tissues. 
 The absorption of Ubidecarenone is enhanced in the presence of lipids. 
 Secretions from the pancreas and bile facilitate emulsification and micelle formation 
 that is required for the absorption of fats. 
 About 95% of Ubidecarenone in circulation exists in its reduced form as ubiquinol in 
 human. 
  Ubidecarenone absorption and bioavailability varies greatly depending on the type of 
 Ubidecarenone formulation.  
 
DISTRIBUTION 
 Ubidecarenone level in body is estimated to be approximately 0.5–1.5 g in a normal 
 adult. 
 Sub cellular distribution of Ubidecarenone show a large portion (40–50%) of 
 Ubidecarenone localized in the mitochondrial inner membrane, with smaller amounts in 
 the other organelles also in the cytosol. 
 Tmax    6 hours. 
 t 1/2    33 hours. 
 
METABOLISM AND EXCRETION 
 Absorbed intact via the lymphatics and concentrated mainly in the liver. 
 Excreted via the bile. 
 Main metabolite was presumed to be a glucuronide of Q acid I [2, 3 dimethoxy-5-
 methyl-6-(30-methyl-50-carboxy-2-pentenyl)-1, 4-benzohydroquinone] formed in the 
 liver. 
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5.1.3 ADVERSE EFFECTS 47 
 Diarrhoea. 
 Loss of appetite. 
 Nausea. 
 Stomach upset. 
 Trouble sleeping. 
 Severe allergic reactions (rash, hives, itching, difficulty in breathing, tightness in the 
 chest, swelling of the mouth, face, lips or tongue). 
 
5.1.4 PRECAUTIONS 
 Liquid forms, chewable tablets, dissolving forms of Ubidecarenone contain sugar, 
alcohol or aspartame. Patients having the history of diabetes, alcohol dependence, liver 
disease, Phenylketonuria (PKU) should take this medication with  caution. 
  During pregnancy, this drug should be used only when clearly needed. 
 
5.1.5 DRUG INTERACTIONS 
 Chemotherapy medications  
   Ubidecarenone’s anti oxidant effect might make some chemotherapy drugs 
    less effective. 
 Daunorubicin and doxorubicin 
    Ubidecarenone may help to reduce the toxic effects on the heart caused by 
 daunorubicin (cerubidin) and doxorubicin (Adiramycin). 
 Blood pressure medications   
   Ubidecarenone may work with blood pressure medications to lower blood pressure. 
In a clinical study of people taking blood pressure medications, adding Ubidecarenone 
supplements allowed them to lower the doses of these medications. 
 Blood thinning medications  
   Ubidecarenone, when it is given Warfarin (Coumadin) or Clopidigrel (plavix) 
it reduces the blood thinning effect of blood.Ubidecarenone supplements when given with 
Betaxolol drops (Betoptic), a beta blocker medication used to treat glaucoma, it reduces 
heart related side effects. 
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 Other medications that can lower the level of Ubidecarenone in the body include 
 Statins for cholesterol, including Atorvastatin (lipitor), Lovastatin (Mevacor), 
Pravastatin (Pravachol) and Simvastatin (Zocor). 
 Beta-blockers for high blood pressure, such as Atenolol (Tenormin), Labetolol 
(Normodyne), Metoprolol (Lopressor or toprol) and Propranolol (Inderal). 
 Tricyclic antidepressant medications, including Amitriptyline (Elavil), Doxepin 
(Sinequan) and Imipramine (Tofranil). 
  
5.1.6 DOSAGE INFORMATION 44 
 For most disease and other neurological conditions found doses ranging from 400 to 
 1200mg daily in divided doses.  
 For breast cancer 390mg daily. 
 For Parkinson’s disease doses ranging from 400-1200mg daily to be effective. 
 For cardiovascular disease dosages range from 100 to 200mg/day. 
 Dosages of upto 15mg/kg/day are being employed in the case of mitochondrial 
 cytopathy patients. 
 
5.1.7 TOXICITY 
   Ubidecarenone appears to be quite safe, even at the highest doses cited in the 
literature. Occasional reports of nausea, anorexia or skin eruptions have been reported 
with Ubidecarenone supplementation. 
 
5.1.8 USES 45, 48 
   Ubidecarenone supplements, either by themselves or in with other drug 
therapies, may help to prevent or treat the following conditions: 
 After Heart Attack. 
 Heart failure (HF). 
 Hypertension. 
 Hyperlipidemia. 
 Diabetes. 
 
Drug profile 
 
Department of Pharmaceutics, Madras Medical College Page 34 
 
 Heart damage caused by chemotherapy. 
 Heart surgery. 
 Gum (Periodontal) disease. 
 
  Preliminary clinical studies also suggest that Ubidecarenone may: 
 
 Improve immune function in people with HIV or AIDS. 
 Increase sperm motility, improving male fertility. 
  Used as part of the treatment for Parkinson's disease. 
 Improve exercise ability in people with angina. 
 Helps to prevent migraines. 
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6. EXCIPIENT PROFILE  
6.1 MANNITOL49 
6.1.1. Non proprietary Names 
BP  : Mannitol  
JP  : D-Mannitol  
PhEur : Mannitol  
USP-NF : Mannitol 
6.1.2. Synonyms 
  Cordycepic acid,  E421,  Emprove,   manna sugar, D-mannite,  mannite, 
mannitolum, Mannogem,  Pearlitol. 
6.1.3. Functional Category 
  Sweetening agent, tablet and capsule diluent, tonicity agent, vehicle (bulking 
agent) for lyophilized preparations. 
6.1.4. Description 
   Mannitol is D-mannitol. It is a hexahydric alcohol related to mannose and is 
isomeric with sorbitol. Mannitol occurs as a white, odourless, crystalline powder or free-
flowing granules. It has a sweet taste, approximately as sweet as glucose and half as sweet 
as sucrose, and imparts a cooling sensation in the mouth. 
6.1.5. Chemical Name  : D-Mannitol 
6.1.6. Empirical Formula : C6H14O6 
6.1.7. Molecular Weight  : 182.17 
 
6.1.8. Applications in Pharmaceutical Formulation or Technology 
 Mannitol is widely used in pharmaceutical formulations and food products. 
 In pharmaceutical preparations it is primarily used as a diluent (10–90% w/w) in 
 tablet formulations. 
 Mannitol is commonly used as an excipient in the manufacture of chewable tablet 
 formulations because of its negative heat of solution, sweetness and ‘mouth feel’. 
 
6.1.9. Typical properties 
Density (Bulk)  : 0.430 g/cm3 for powder 
       0.7 g/cm3 for granules 
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Density (Tapped)  : 0.734 g/cm3 for powder 
       0.8 g/cm3 for granules. 
 
Density (True)  : 1.514 g/cm3 
 
6.1.10. Stability and Storage Conditions 
  Mannitol is stable in the dry state and in aqueous solutions. In solution, 
mannitol is neither attacked by cold, dilute acids or alkalis, nor by atmospheric oxygen in 
the absence of catalysts. The bulk material should be stored in a well-closed container in a 
cool, dry place. 
6.1.11. Incompatibilities 
   Mannitol solutions, 20% w/v or stronger, may be salted out by potassium 
chloride or sodium chloride. 
6.1.12. Safety  
  After intravenous injection, mannitol is not metabolized to any appreciable 
extent and is minimally reabsorbed by the renal tubule, about 80% of a dose being 
excreted in the urine in 3 hours. 
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                             6.2 CROSPOVIDONE49 
6.2.1. Non proprietary Names 
BP     : Crospovidone  
PhEur   : Crospovidone 
USP-NF      : Crospovidone  
6.2.2. Synonyms 
   Crospovidonum, Crospopharm, crosslinked povidone, E1202, 
Kollidon   CL, Kollidon CL-M, Polyplasdone XL, PolyplasdoneXL-10, 
polyvinylpolypyrrolidone,  PVPP, 1-vinyl-2-pyrrolidinone homopolymer. 
6.2.3. Functional category  
 Tablet disintegrant 
6.2.4. Description  
         Crospovidone is a white to creamy white, finely divided, free flowing, 
 practically tasteless, odourless or nearly odourless, hygroscopic powder. 
6.2.5. Chemical name  
 1-Ethenyl-2-pyrrolidinone homo polymer 
6.2.6. Empirical formula : (C6H9NO)n 
6.2.7. Molecular weight  : >1 000000 
6.2.8. Applications in Pharmaceutical Formulation or Technology 
 Crospovidone is a water-insoluble tablet disintegrant and dissolution agent 
 used at 2–5% concentration in tablets prepared by direct- compression  or wet- 
 and  dry-granulation methods. 
 Crospovidone can   also be used   as   a   solubility enhancer. 
6.2.9. Typical properties 
 Acidity/Alkalinity :   pH= 5.0–8.0  (1% W/V Aqueous  Slurry). 
 Density            : 1.22 g/cm3 
 
6.2.10. Stability and storage conditions 
   Since Crospovidone is hygroscopic, it should be stored in an airtight 
 container in a cool, dry place. 
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6.2.11. Incompatibilities 
 Crospovidone is compatible with most organic and inorganic pharmaceutical  
  ingredients. 
 It is when exposed to high water level forms a molecular adducts with some  
  materials. 
6.2.12. Safety 
 Crospovidone is non toxic and non irritant material. 
 No adverse effects associated with Crospovidone. 
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6.3 POLOXAMER 40749 
6.3.1. Non proprietary Names 
BP     : Poloxamers 
PhEur : Poloxamers 
USP-NF : Poloxamer  
6.3.2. Synonyms 
  Lutrol, pluronic, poloxalkol 
6.3.3. Functional Category 
  Dispersing agent, emulsifying agent, solubilising agent, tablet lubricant, 
wetting agent. 
6.3.4. Description 
                  Poloxamers generally occurs as white, waxy, free flowing prilled granules or as 
cast solids. They are practically odourless and tasteless.  
6.3.5. Chemical name 
  α-Hydro-o-hydroxypoly(oxyethylene)poly(oxypropylene) poly- (oxyethylene) 
block copolymer. 
6.3.6. Applications in Pharmaceutical Formulation or Technology 
 Poloxamer 188 is used as a wetting agent, stool lubricant in constipation. 
 Poloxamers may be used as wetting agents in eye drop formulations, in the treatment 
 of kidney stones and as a skin wound cleansers. 
 Poloxamer 338 and 407 are used in solutions for contact lens care. 
Table No. 3: Applications of Poloxamer 
Uses of poloxamer 
Use Concentration (%) 
Fat emulsifier 0.3 
Flavour emulsifier 0.3 
Fluorocarbon emulsifier 2.5 
Gelling agent 15-50 
Spreading agent 1 
Stabilizing agent 1-5 
Tablet coating 10 
Tablet excipient 5-10 
Wetting agent 0.01-5 
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6.3.7. Typical properties 
                    Acidity /alkalinity   :    pH =5.0-7.4 for a 2.5% w/v aqueous solution  
                    Density                    :    1.06 g/cm3 at 258ºC  
6.3.8. Stability and storage conditions 
 Poloxamers are stable materials. 
 Aqueous solutions are stable in acids, alkalis and metal ions but it support mold  
  growth. 
 The bulk material should be stored in a well closed container in a cool dry place. 
6.3.9. Incompatibilities 
 Depending on the relative concentrations, Poloxamer 188 is incompatible with 
Phenols and Parabens. 
6.3.10. Safety 
 Poloxamers are generally regarded as non toxic and non irritant material. 
 Poloxamers are not metabolized in the body. 
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6.4 SACCHARIN SODIUM49 
6.4.1. Non proprietary Names 
 BP    : Saccharin Sodium 
 JP    : Saccharin Sodium Hydrate 
 PhEur    : Saccharin Sodium 
 USP-NF : Saccharin Sodium 
6.4.2. Synonyms 
  1,2-Benzisothiazolin-3-one 1,1-dioxide, sodium salt, sodium benzosulfimide, 
soluble gluside, soluble saccharin, sucaryl Sodium. 
6.4.3 Functional category :  Sweetening agent 
6.4.4. Description 
  Saccharin sodium occurs as a white, odourless or faintly aromatic, 
efflorescent, crystalline powder. It has an intensely sweet taste, with a metallic aftertaste. 
 
6.4.5. Chemical Name      : 1,2-Benzisothiazol-3(2H)-one 1,1-dioxide, sodium salt. 
6.4.6. Empirical Formula     : C7H4NNaO3S 
6.4.7. Molecular Weight      : 205.16 
6.4.8. Functional Category   : Sweetening agent 
 
6.4.9. Applications in Pharmaceutical Formulation or Technology 
 Saccharin sodium is an intense sweetening agent used in beverages, food products, 
 and pharmaceutical formulations such as tablets, powders, medicated confectionery,
 gels, suspensions, liquids, and mouthwashes. It is also used in vitamin preparations. 
 Saccharin sodium enhances flavour systems and may be used to mask some 
 unpleasant taste characteristics. 
6.4.10. Stability and Storage Conditions  
 Saccharin sodium is stable under the normal range of conditions employed in 
 formulations. 
 Saccharin sodium should be stored in a well-closed container in a cool, dry place. 
6.4.11. Incompatibilities  : None 
6.4.12. Safety   : It is regarded as a safe, intense sweetener. 
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6.5 ASPARTAME49 
6.5.1. Non proprietary Names 
 BP  :  Aspartame 
 PhEur  :  Aspartame  
 USP-NF :  Aspartame 
6.5.2. Synonyms 
 Canderel, E951, Equal, methyl N-L-phenylalaninate, Natra taste, Pal sweet diet, 
Sasnecta, SC-18862, Tri-sweet. 
 
6.5.3. Description  
  Aspartame occurs as an off white, almost odourless crystalline powder with an 
 intensely sweet taste. 
 
6.5.4. Functional category  : Sweetening agent 
6.5.5. Empirical formula   : C14H18N2O5  
6.5.6. Molecular weight  : 294.30 
 
6.5.7. Applications in pharmaceutical technology 
 Aspartame is used as an intense sweetening agent in beverage products, food 
 products and table top sweeteners tablets and other preparations. 
 It enhances flavour and masks the unpleasant taste characteristics, its sweetening 
 power is 180-200 times that of sucrose. 
6.5.8. Typical properties 
 Acidity/alkalinity  : pH 4.5-6.0 (0.8% w/v aqueous solution) 
 Density (bulk)   : 0.5-0.7 g/cm3 for granular grade 
     : 0.2-0.4 g/cm3 for powder grade 
     : 0.29 g/cm3 (tapped density) 
6.5.9. Stability and storage conditions 
 Aspartame is stable in dry conditions. 
 In presence of moisture it undergoes hydrolysis and forms degradation products.  
 
6.5.10. Incompatabilities  
 Aspartame is incompatible with dicalcium phosphate and magnesium stearate. 
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6.5.11. Safety 
  Aspartame is widely used in oral formulations as sweeteners but it undergoes 
metabolism and forms toxic by products like phenyl alanine, methanol and aspartic acid. 
So it is not recommended in patients with phenylketonuria. Other side effects on 
consumption of aspartame results in headaches, memory loss, gastrointestinal symptoms 
and dermatological symptoms.  
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6.6 COLLOIDAL SILICON DIOXIDE49 
6.6.1. Nonproprietary Names 
BP : Colloidal anhydrous silica  
PhEur : Silica colloidalis anhydrica 
USPNF : Colloidal silicon dioxide 
6.6.2. Synonyms  
  Aerosil, Cab-O-Sil, colloidal silica, light anhydrous silicic acid, silicic 
anhydride, silicon dioxide fumed. 
6.6.3. Description  
  It is a submicroscopic fumed silica with a particle size of about 15 nm. It is a 
light, loose, bluish-white-colored, odorless, tasteless, non-gritty amorphous powder. 
6.6.4. Chemical Name  : Silica 
6.6.5. Empirical Formula : SiO2 
6.6.6. Molecular Weight  : 60.08 
6.6.7. Functional Category : Adsorbent, anti caking agent, glidant, tablet       
       disintegrant, viscosity-increasing agent. 
6.6.8. Applications in Pharmaceutical Formulation or Technology 
 It is widely used in pharmaceuticals, cosmetics, and food products. 
 Also used to stabilize emulsions and as a thixotropic thickening and suspending 
 agent in gels and semisolid preparations. 
 Also used as a tablet disintegrant and as an adsorbent,  dispersing agent for 
 liquids in powders. 
6.6.9. Typical Properties 
 Acidity/alkalinity pH = 3.8–4.2 (4% w/v aqueous dispersion)  
 Density (bulk) 0.029–0.042 g/cm3 
6.6.10. Stability and Storage Conditions 
 It is hygroscopic but adsorbs large quantities of water without liquefying.  
 Colloidal silicon dioxide powder should be stored in a well-closed container. 
6.6.11. Incompatibilities 
  Incompatible with diethylstilbosterol preparations. 
6.6.12. Safety 
  Colloidal silicon dioxide is widely used in oral and topical pharmaceutical 
products and is generally regarded as an essentially non-toxic and non-irritant excipient. 
Excipient profile 
 
Department of Pharmaceutics, Madras Medical College Page 45 
 
6.7 SODIUM STEARYL FUMARATE49 
6.7.1. Non-proprietary Names 
BP      : Sodium Stearyl Fumarate 
PhEur         : Sodium Stearyl Fumarate 
USP-NF     : Sodium Stearyl Fumarate 
6.7.2. Synonyms 
  Fumaric acid, octadecyl ester, sodium salt; natrii stearylis fumaras; Pruv; 
sodium monostearyfumarate. 
6.7.3 Description 
 Sodium stearyl fumarate is a fine, white powder with agglomerates of flat, circular-
shaped particles. 
6.7.4. Functional Category     : Tablet and capsule lubricant. 
6.7. 5. Chemical Name            :  2-Butenedioic acimd, onooctadecyl ester, sodium salt  
6.7.6. Empirical Formula       : C22H39NaO4 
6.7.7. Molecular Weight         : 390.5 
6.7.8. Applications in Pharmaceutical Formulation or Technology 
 Sodium stearyl fumarate is used as a lubricant in capsule and tablet formulations 
 at 0.5–2.0% w/w concentration. 
 It is also used in certain food applications. 
6.7.9. Typical  properties 
Acidity/alkalinity : pH = 8.3 for a 5% w/v aqueous solution at 90ºC. 
Density   : 1.107 g/cm3  
Density (bulk)  : 0.2–0.35 g/cm3 
Density (tapped : 0.3–0.5 g/cm3 
6.7.10. Stability and storage conditions 
  The bulk material should be stored in a well-closed container in a cool, dry 
 place. 
 6.7.11. Incompatibilities 
  Sodium stearyl fumarate is reported to be incompatible with chlorhexidine 
 acetate. 
6.7.12. Safety  
  Sodium stearyl fumarate is used in oral pharmaceutical formulations and is 
generally regarded as a nontoxic and non-irritant material. 
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7. DISEASE PROFILE44 
`  Ubidecarenone is a compound found naturally in the human body. Because of 
its ubiquitous presence in nature and its quinone structure (similar to that of vitamin K), 
Ubidecarenone is also known as ubiquinone.  
  Tissue deficiencies or subnormal serum levels of Ubidecarenone have been 
reported in a wide range of medical conditions, including  
 Cardiovascular disease. 
 Neuromuscular disease.  
 Mitochondrial disorders. 
 Acquired Immune Deficiency Syndrome. 
 Cancer. 
 Migraine 
 Thyroid Disorders. 
 Periodontal Disease. 
 Gastric Ulcer. 
 Obesity. 
 Asthma. 
 Diabetes. 
 Muscular dystrophy. 
 Allergy. 
7.1 CARDIOVASCULAR DISEASES  
 7.1.1 Hypertension44 
  Hypertension is the condition in which systolic blood pressure is above 
140mm of Hg and diastolic pressure above 90mm of Hg. Epidemiological studies have 
confirmed that higher the blood pressure greater the risk of cardiovascular disease. 
Mechanism behind antihypertensive effect of Ubidecarenone is its ability to induce 
vasodilation via decreased peripheral resistance in the vasculature. Ubidecarenone’s 
antioxidant properties results in quenching of free radicals that cause inactivation of 
endothelium-derived relaxing factor and/or fibrosis of arteriole smooth muscle. 
7.1.2 Heart Failure 50 
  Ubidecarenone has the promising beneficial effect in heart failure when it is 
given alone or along with standard therapies. Ubidecarenone improves the cardiovascular 
function by increasing energy production, increases contraction of cardiac muscle. 
Disease Profile 
 
Department of Pharmaceutics, Madras Medical College Page 47 
 
 7.1.3 Other Cardiovascular diseases 
   Ubidecarenone is also useful in conditions like 
 Cardiomyopathy. 
 Angina. 
 Arrhythmias. 
 Acute myocardial infarction.  
  Ubidecarenone supplementation improves the cardiovascular function through 
the following mechanism,  
 Enhanced energy production. 
  Improved contractility of cardiac muscle.  
 Potent antioxidant activity. 
 Prevention of LDL oxidation. 
 
7.1.4 Hyperlipidemia and Statin Drugs 51, 52 
  Ubidecarenone is essential in mitochondrial respiration.  HMG CoA reductase 
inhibitors used in the treatment of hyperlipidemia interfere with the production of 
mevalonic acid, which is a precursor in the synthesis of Ubidecarenone. This result in 
reduction of Ubidecarenone levels in serum which produces Rhabdomylosis. Thus 
Ubidecarenone supplement is essential in statin therapy. 
7.2 NEUROLOGICAL CONDITIONS 
7.2.1 Parkinson’s Disease53 
  It is an extrapyramidal motor disorder characterized by rigidity, tremor and 
hypokinesia with secondary manifestations like defective posture, mask-like face, 
sialorrhoea, dysphagia and dementia. It is a degenerative neurological disorder for which 
no treatment has been shown to slow down the progression. Ubidecarenone appears to 
slow the progressive deterioration of function in Parkinson disease. Ubidecarenone play a 
role in the cellular dysfunction found in Parkinson’s disease (PD), providing a protective 
agent for Parkinsonian patients. 
7.2.2 Huntington’s Disease  
  Huntington’s disease (HD) is a progressive neurodegenerative disease 
characterized by abnormalities in mitochondrial morphology and activity. This condition 
is also treated by Ubidecarenone. 
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7.3 MITOCHONDRIAL DISORDERS54 
 Mitochondrial disorders occur due to deficiency of Ubidecarenone in the cells. 
Ubidecarenone deficiency has been associated with five major clinical phenotypes:      
i) Encephalomyopathy  
ii) Severe infantile multisystemic disease  
iii) Cerebellar ataxia  
iv)  Isolated Myopathy  
v)  Nephritic syndrome.  
 Ubidecarenone supplementation typically in dosages from 30-300 mg daily is 
given to improve the mitochondrial disorders. 
 
7.4 ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) 55  
  AIDS is a complex disease that is associated with a wide range of nutritional 
deficiencies and immunological disorders. Since oxidative stress is believed to be involved 
in the pathogenesis of AIDS-related diseases, the antioxidant activity of Ubidecarenone 
helps in preventing AIDS-related diseases such as cardiomyopathy and lipodystrophy that 
can be caused by oxidative stress. Blood levels of Ubidecarenone are lower in AIDS 
patients and supplementation with 200 mg/day has been shown to increase T4/T8 ratios in 
these individuals. 
 
7.5 CANCER 56, 57 
  Decreased levels of Ubidecarenone have been found in plasma of women with 
breast cancer and in cancerous breast tissue. Oxygen derived radicals are able to cause 
damage to membranes, mitochondria and macromolecules including proteins, lipids and 
DNA. Mechanisms for Ubidecarenone in cancer include immune system enhancement and 
antioxidant activity. 390 mg of Ubidecarenone daily results in tumor regression and 
disappearance of previously diagnosed metastasis. Ubidecarenone can be depleted by the 
use of the chemotherapeutic drug doxorubicin (Adriamycin®), resulting in cardiotoxicity 
if a high enough cumulative dose is achieved. Ubidecarenone is a potential anticancer 
agent and it reduces the risk of prostate cancer.  
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7.6 MIGRAINE 58 
  Migraine is also due to the impaired energy metabolism in brains and this can 
be treated by Ubidecarenone. Ubidecarenone improves energy metabolism and the dose of 
300mg/day improves the condition of migraine and it is well tolerated.  
 
7.7 THYROID DISORDERS44 
   Decreased levels of Ubidecarenone was found in plasma and thyroid tissue of 
individuals with certain forms of hyperthyroidism. In Grave’s disease, excessive thyroid 
hormone stimulation and subsequent activation of mitochondrial function results in 
subnormal Ubidecarenone concentrations and thus it can be treated with Ubidecarenone. 
 
7.8 PERIODONTAL DISEASE 
  Periodontal disease affects about 60% of young adults and 90% of individuals 
over the age of 65. Although proper oral hygiene is helpful, many people suffer from 
intractable gingivitis, often requiring surgery and resulting in eventual loss of teeth. 
Healing and repair of periodontal tissues requires efficient energy production, which 
depends on an adequate supply of Ubidecarenone. Gingival biopsies revealed subnormal 
tissue levels of Ubidecarenone in 60% to 96% patients with periodontal disease and low 
levels of Ubidecarenone in leukocytes in 86% of cases. These findings indicate that 
periodontal disease is frequently associated with Ubidecarenone deficiency. 
 
7.9 GASTRIC ULCER 
  Susceptibility to gastric ulceration is related to the balance between ulcer 
promoting factors (such as excessive gastric acidity and infection with Helicobacter 
pylori) and resistance factors (such as tissue integrity, production of protective mucus and 
repair mechanisms). Free-radical damage is one of the primary mechanisms by which 
external factors induce gastric injury and Peptic ulceration. Since, Ubidecarenone 
possesses antioxidant activity, it is capable of preventing ulceration by reducing the 
amount of free-radical damage. In addition, the production of protective mucus and the 
rapid cell turnover of gastric mucosa are highly energy dependent processes, which require 
the presence of adequate amounts of Ubidecarenone. 
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7.10 OBESITY 
  The Obesity is associated in some cases with impaired energy production. This 
abnormality may be in part genetically determined. Individuals with a family history of 
obesity have a 50% reduction in their thermogenic response to meals, suggesting the 
presence of an hereditary defect in energy output. Ubidecarenone is an essential cofactor 
for energy production, thus Ubidecarenone deficiency is a contributing factor for obesity. 
 
7.11 MUSCULAR DYSTROPHY 
  In muscular dystrophy, low levels of Ubidecarenone has been found in muscle 
mitochondria and it is involved in pathogenesis of cardiac disease, which occurs in 
virtually every form of muscular dystrophy and myopathy. 
 
7.12 DIABETES  
  The electron-transport chain is integrally involved in carbohydrate 
metabolism. Serum Ubidecarenone levels in Type 2 diabetic patients are decreased and 
may be associated with subclinical diabetic cardiomyopathy and it is treated with 
Ubidecarenone supplementation. 
 
7.13 ASTHMA 
  In case of asthma, low Ubidecarenone levels are found and it create oxidative 
stress and produces chronic mucosal inflammation. Thus Asthma can be treated with 
combination of corticosteroids and Ubidecarenone to give better effect.   
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08. MATERIALS AND METHODS 
 
Table No.4: LIST OF EQUIPMENTS 
 
 
S.No 
 
Instruments/Equipments 
 
Manufacturer 
1 Mixer with sigma blade Lumix food processor 
2 ASTM Sieve No 40(425µm) Electro Pharma 
3 ASTM Sieve No 60(250µm) Electro Pharma 
4 Moisture Analyzer OHAUS MB 45 
5 Tap density tester USP I Electrolab ETD-1020 
6 Friabilator USP Electrolab EF-1W 
7 Analytical balance OHAUS adventurer 
8 Top loading balance Essae  Teraoka Limited (model DS 450cw) 
9 Disintegration tester USP Electrolab ED-2L 
10 
16 station single Rotary 
compression machine 
Cadmach , Ahmedabad, India 
11 Hardness tester 
Dr.Schleuniger Pharmatron model 5Y tablet 
tester 
12 Vernier calliper Mitutoyo 
13 Dissolution Apparatus Electrolab 8 Station (TDT - 08L) 
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Table no.5: LIST OF MATERIALS  
 
 
S.No 
 
Material 
 
Manufacturer 
 
Applications 
1 Ubidecarenone Sigma Aldrich, USA API 
2 
Pearlitol flash 
(Mannitol with starch) 
Roquette, France Diluent 
3 Saccharin Sodium Nutrinova, Germany Sweetener 
4 Aspartame Nutrinova, Germany Sweetener 
5 Mint flavour Firmenich, Switzerland Flavouring agent 
6 Orange flavour Firmenich, Switzerland Flavouring agent 
7 
Crospovidone 
(Polyplasdone XL 10) 
ISP Technologies, 
USA 
Disintegrant 
8 Poloxamer 407 (Lutrol Micro 127) BASF, Germany Wetting agent 
9 Colloidal Silicon Dioxide (Cabosil) Cabot Sanmar , USA Glidant 
10 Sodium Stearyl Fumarate  (Pruv) JRS Pharma, Germany Lubricant 
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PREFORMULATION STUDIES 
8.1 Drug - Excipient Compatibility Study 59 
  The drug and excipients were taken in appropriate ratio and mixed well in a 
polybag and it was passed into 40 ASTM Sieve and then taken in 2ml glass vials (USP 
TYPE I). The filled vials were kept at 40 ± 2ºC/ 75 ± 5% RH and the samples withdrawn  
initially , 2nd week, 4th week and it was analyzed for the following, 
 Appearance. 
 Assay. 
 Water content. 
 
Table no.6:  Drug– Excipient Compatibility Studies 
S.No Drug-Excipient Ratio 
1 Ubidecarenone – Pearlitol Flash 1:0.5 
2 Ubidecarenone – Crospovidone 1:0.25 
3 Ubidecarenone – Poloxamer 407 1:0.25 
4 Ubidecarenone – Aspartame 1:0.25 
5 Ubidecarenone – Saccharin Sodium 1:0.25 
6 Ubidecarenone – Mint Flavour 1:0.25 
7 Ubidecarenone – Orange Flavour 1:0.25 
8 Ubidecarenone – Colloidal Silicon Dioxide 1:0.25 
9 Ubidecarenone – Sodium Stearyl Fumarate 1:0.25 
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8.2 Particle size determination by sieving method 60 
  Tare each test sieve to the nearest 0.1 g. The weight of the empty sieves were 
noted. The test sieves were stacked in the ascending order with sieve with largest aperture 
size on the top and the smallest in the bottom. Replace the lid. An accurately weighed 
sample of 25g was placed on the top of the sieve. The nest of sieves were agitated for 5 
minutes automatically in mechanical shaker. Then the sieves were reassembled carefully 
and the weight of material retained on each sieve was determined. The particle size 
distribution of the raw material was then calculated. 
 
8.3 Bulk Density (ρb)61 
  It is the ratio of total mass of powder to the bulk volume of powder. It was 
measured by pouring the weighed powder into a measuring cylinder. This initial volume 
was called the bulk volume. From this the bulk density was calculated according to the 
formula mentioned below. It is expressed in gm/mL and is given by 
ρb = M/ Vb 
  Where, ρb – Bulk density (g/mL) 
     M - Mass of powder (g) 
                   Vo - Bulk volume of the powder (mL). 
 
8.4 Tapped Density (ρt) 61 
  It was achieved by mechanically tapping a measuring cylinder containing a 
powder sample. After observing the initial volume, the cylinder was mechanically tapped 
and volume readings were taken until little further volume change was observed. The 
mechanical tapping was achieved by raising the cylinder and allowing it to drop under its 
own weight at a specific distance. Devices that rotate the cylinder during tapping may 
minimize any possible separation of the mass during tapping down.  The tapped volume 
was measured by tapping the powder to constant volume. It is expressed in g/mL and is 
given by  
ρ t =  M/Vt 
   Where, ρt  -  Tapped density (g/mL) 
          M - Mass of powder (g) 
                 Vt -  Tapped volume of the powder (mL). 
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8.5   Compressibility Index61 
  It indicates powder flow properties. It was measured for determining the 
relative importance of interparticulate interactions. It is expressed in percentage and is 
given by 
    CI = (ρt – ρb) / ρt * 100 
Where, CI – Compressibility Index 
        ρt  ‐  Tapped density, 
        ρb ‐   Bulk density 
 
8.6   Hausner’s ratio61 
 Hausner’s ratio is an index of ease of powder flow, it is calculated by following 
formula. 
                                                  HR = ρt\ ρb 
      Where, HR - Hausner’s ratio 
                    ρt ‐ Tapped density 
                    ρb ‐ Bulk density 
 
Table No.7: Scale of Flowability 59 
Compressibility Index (%) Flow Character Hausner’s Ratio 
≤10 Excellent 1.00–1.11 
11-15 Good 1.12-1.18 
16-20 Fair 1.19-1.25 
21-25 Passable 1.26-1.34 
26-31 Poor 1.35-1.45 
32-37 Very poor 1.46-1.59 
>38 Very Very poor >1.60 
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8.7  Angle of repose 61 
  This is the maximum angle possible between the surface of the pile of powder 
and horizontal plane. The frictional forces in the loose powder can be measured by 
Angle of repose. The tangent of angle of repose is equal to the coefficient friction between 
the particles. Hence the rougher and more irregular surface of particles, the greater will be 
angle of repose.  
  Angle of repose was determined by using funnel method. Powder was poured 
from a funnel that can be raised vertically until a maximum cone height h, was obtained. 
Diameter of heap d was measured. 
 The angle of repose θ, was calculated by the formula, 
       tan  θ    =     h/r 
                           θ     =     tan-1 (h/r) 
Where,   θ - Angle of repose 
         h - Height of the pile (cm) 
         r - Radius of the pile (cm) 
 
Table No. 8: Flow properties and corresponding Angles of Repose60 
 
Flow property 
Angle of  
Repose (Degrees) 
Excellent 25-30 
Good 31-35 
Fair – aid not needed 36-40 
Passable- may hang up 41-45 
Poor –must agitate, vibrate 46-55 
Very poor 56-65 
Very Very poor >66 
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8.8 Water Determination by Karl Fischer Titration60 
  Four tablets were powdered in a mortar and it was taken as analyte. The Karl 
Fischer reagent was added from automated burette and the endpoint was determined 
electrometrically. At the endpoint of the titration, a slight excess of the reagent increased 
the flow of current which was measured in milliamperes. The air in the system kept dry 
with a suitable dessicant and the titration vessel was purged by means of a stream of dry 
nitrogen or current of dry air. 
 
H2O + I2 + SO2 + 3C5H5N + CH3OH  2C5H5N.HI + C5H5NH.SO4CH3 
         Iodine         Pyridine      methanol                   
       (Formation of hydrogen iodide)            
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9. FORMULATION DEVELOPMENT  
 
9.1 Excipient Selection 
 Diluent - Pearlitol Flash (Mannitol with starch). Pearlitol flash is the widely used 
diluent in chewable and orally disintegrating tablets. It is a highly compressible and 
densified material which gives a compact tablet.62 
 Sweetener – A combination of Saccharin Sodium and Aspartame was selected as 
sweetener.49 
  Flavour – A combination of Mint and Orange flavour.62 
 Disintegrant – Crospovidone (Polyplasdone XL 10) is one of the most widely used 
non ionic disintegrant which gives better disintegration at less concentration.63 
 Wetting agent – In chewable tablet, ionic surfactants are avoided because they 
produce irritation on the mucosa. Hence Poloxamer 407 (Lutrol Micro 127) was 
selected which is a non ionic surfactant widely used in oral formulations.64,65 
 Glidant – Colloidal Silicon Dioxide (Cabosil) was selected which is widely used to 
provide flow property and disintegration.66 
 Lubricant – Sodium Stearyl Fumarate (Pruv) was selected since it is the only 
hydrophilic lubricant available in the market. It can be added in higher amounts in 
formulation without compromising on disintegration and dissolution characteristics of 
dosage form.67 
 
9.2 Punch Tooling 
 21 X 10 mm Caplet shaped punch. 
 
9.3 Tablet Weight 
 Each tablet of 1200 mg weight. 
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FLOW CHART FOR OPTIMIZATION OF INGREDIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
Optimized formula for direct compression 
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9.4  Procedure 
Step 1: Ubidecarenone, Pearlitol Flash, Crospovidone, Poloxamer 407, Mint Flavour, 
          Orange Flavour, Aspartame and Saccharin Sodium were sifted through  
               # 40 ASTM sieve. 
Step 2:   The sifted materials of Step 1 was blended in a polybag for 10 min. 
Step 3:  Colloidal silicon dioxide and Sodium stearyl fumarate were sifted through # 60 
          ASTM sieve. 
Step 4:  The sifted materials of Step 3 and materials of Step 2 were mixed in a polybag 
          for 5 min. 
Step 5: The blended materials of Step 4 was compressed in 16 station tablet compression 
         machine using 21 X 10 mm Caplet shaped punch.  
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FLOWCHART FOR MANUFACTURING PROCEDURE OF UBIDECARENONE 
CHEWABLE TABLETS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ubidecarenone,  
Pearlitol flash,  
Crospovidone, 
Poloxamer 407,  
Aspartame,  
Saccharin sodium, 
Mint flavour, 
 Orange flavour. 
 
 
Sieving in  
      ASTM 40  
 
Colloidal silicon dioxide,       
Sodium stearyl fumarate 
 
Mixed in Polybag 
(Blend I) Mixed in Polybag (Blend II) 
Mix Blend I and II 
Sieving in  
      ASTM 60 
Compression 
Post compression        
study 
Chewable tablets of 
Ubidecarenone  
Stability 
studies 
Pre compression 
study 
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9.5 Formulation Trials for optimizing concentration of Flavours 
  The blends were prepared by varying the concentration of orange flavour, mint 
flavour and the concentration of all the other ingredients were kept constant. The tablets were 
compressed by direct compression technique in 16 station tablet compression machine using 
21 x 10 mm caplet shaped punches.   
 
Table No.9: Trials for optimizing concentration of Flavours 
S.No Ingredients 
mg / tablet 
A I A II A III A IV 
1 Ubidecarenone 400.00 400.00 400.00 400.00 
2 Pearlitol Flash 757.50 757.50 757.50 757.50 
3 Crospovidone 5.00 5.00 5.00 5.00 
4 Poloxamer 407 5.00 5.00 5.00 5.00 
5 Aspartame 5.00 5.00 5.00 5.00 
6 Saccharin Sodium 5.00 5.00 5.00 5.00 
7 Mint Flavour 2.50 5.00 7.50 10.00 
8 Orange Flavour 10.00 7.50 5.00 2.50 
9 Colloidal Silicon Dioxide 5.00 5.00 5.00 5.00 
10 Sodium Stearyl Fumarate 5.00 5.00 5.00 5.00 
Total 1200.00 1200.00 1200.00 1200.00 
 
  The formulated tablets were evaluated and concentration of flavours were 
optimized based on aroma sensation testing by volunteers. 
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9.6 Formulation trials for optimizing concentration of Sweeteners 
 The blends were prepared by varying the concentration of aspartame, saccharin 
sodium and the concentration of all the other ingredients were kept constant. The tablets were 
compressed by direct compression technique in 16 station tablet compression machine using 
21 x 10 mm caplet shaped punches.   
 
Table No.10: Trials for optimizing concentration of Sweeteners 
S.No Ingredients 
mg / tablet 
B I B II B III B IV 
1 Ubidecarenone 400 400 400 400 
2 Pearlitol Flash 742.5 742.5 742.5 742.5 
3 Crospovidone 5.00 5.00 5.00 5.00 
4 Poloxamer 407 5.00 5.00 5.00 5.00 
5 Aspartame 5.00 10.00 15.00 20.00 
6 Saccharin Sodium 20.00 15.00 10.00 5.00 
7 Mint Flavour 10.00 10.00 10.00 10.00 
8 Orange Flavour 2.5 2.5 2.5 2.5 
9 Colloidal Silicon Dioxide 5.00 5.00 5.00 5.00 
10 Sodium Stearyl Fumarate 5.00 5.00 5.00 5.00 
 
Total 
1200.00 1200.00 1200.00 1200.00 
 
  The formulated tablets were evaluated and Concentration of Sweeteners were 
optimized based on taste evaluation by volunteers. 
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9.7 Formulation trials for optimizing concentration of Disintegrant 
  The blends were prepared by varying the concentration of Crospovidone 
(Polyplasdone XL10) and the concentration of all the other ingredients were kept constant. 
The tablets were compressed by direct compression technique in 16 station tablet 
compression machine using 21 x 10 mm caplet shaped punches.   
 
Table No.11: Trials for optimizing concentration of Disintegrant 
S.No Ingredients 
mg / tablet 
C I C II C III C IV 
1 Ubidecarenone 400.00 400.00 400.00 400.00 
2 Pearlitol Flash 727.5 707.5 687.5 667.5 
3 Crospovidone 20.00 40.00 60.00 80.00 
4 Poloxamer 407 5.00 5.00 5.00 5.00 
5 Aspartame 20.00 20.00 20.00 20.00 
6 Saccharin Sodium 5.00 5.00 5.00 5.00 
7 Mint Flavour 10.00 10.00 10.00 10.00 
8 Orange Flavour 2.50 2.50 2.50 2.50 
9 Colloidal Silicon Dioxide 5.00 5.00 5.00 5.00 
10 Sodium Stearyl Fumarate 5.00 5.00 5.00 5.00 
Total 1200.00 1200.00 1200.00 1200.00 
 
  The formulated tablets were evaluated and concentration of Crospovidone was 
optimized based on the disintegration time of tablets. 
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9.8 Formulation trials for optimizing concentration of Wetting Agent 
 The blends were prepared by varying the concentration of Poloxamer 407 (wetting 
agent) and the concentration of all the other ingredients were kept constant. The tablets were 
compressed by direct compression technique in 16 station tablet compression machine using 
21 x 10 mm caplet shaped punches.   
 
Table No.12: Trials for optimizing of Concentration of Wetting Agent 
S.No Ingredients 
mg / tablet 
D I D II D III D IV 
1 Ubidecarenone 400.00 400.00 400.00 400.00 
2 Pearlitol Flash 692.5 687.5 682.5 677.5 
3 Crospovidone 60.00 60.00 60.00 60.00 
4 Poloxamer 407 - 5.00 10.00 15.00 
5 Aspartame 20.00 20.00 20.00 20.00 
6 Saccharin Sodium 5.00 5.00 5.00 5.00 
7 Mint Flavour 10.00 10.00 10.00 10.00 
8 Orange Flavour 2.50 2.50 2.50 2.50 
9 Colloidal Silicon Dioxide 5.00 5.00 5.00 5.00 
10 Sodium Stearyl Fumarate 5.00 5.00 5.00 5.00 
Total 1200.00 1200.00 1200.00 1200.00 
 
  The formulated tablets were evaluated and concentration of poloxamer 407 
was optimized based on their dissolution profile of tablets. 
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9.9 Formulation trials for optimizing concentration of Glidant &          
 Lubricant 
  The blends were prepared by varying the concentration of glidant (colloidal 
silicon dioxide), lubricant (Sodium stearyl fumarate) and the concentration of all the other 
ingredients were kept constant. The tablets were compressed by direct compression technique 
in 16 station tablet compression machine using 21 x 10 mm caplet shaped punches.  
 
Table No.13: Trials for optimizing of Concentration of Glidant & Lubricant 
S.No Ingredients 
mg / tablet 
E I E II E III E IV 
1 Ubidecarenone 400.00 400.00 400.00 400.00 
2 Pearlitol Flash 644.5 656.5 680.5 668.5 
3 Crospovidone 60.00 60.00 60.00 60.00 
4 Poloxamer 407 10.00 10.00 10.00 10.00 
5 Aspartame 20.00 20.00 20.00 20.00 
6 Saccharin Sodium 5.00 5.00 5.00 5.00 
7 Mint Flavour 10.00 10.00 10.00 10.00 
8 Orange Flavour 2.50 2.50 2.50 2.50 
9 Colloidal Silicon Dioxide 24.00 18.00 6.00 12.00 
10 Sodium Stearyl Fumarate 24.00 18.00 6.00 12.00 
Total 1200.00 1200.00 1200.00 1200.00 
 
 The formulated tablets were evaluated for its physical characteristics such as sticking, 
picking, striation and the concentration of glidant (Cabosil) and lubricant (Sodium stearyl 
fumarate) was optimized. 
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Formulation of Optimized batch 
Table No.14: Formula for Optimized Batch (E III) 
S.No Ingredients mg / tablet 
1 Ubidecarenone 400.00 
2 Pearlitol Flash 680.5 
3 Crospovidone 60.00 
4 Poloxamer 407 10.00 
5 Aspartame 20.00 
6 Saccharin Sodium 5.00 
7 Mint Flavour 10.00 
8 Orange Flavour 2.50 
9 Colloidal Silicon Dioxide 6.00 
10 Sodium Stearyl Fumarate 6.00 
Total 1200.00 
 
  The optimized formulation blend was mixed uniformly and it was compressed 
by direct compression technique in 16 station tablet compression machine using 21 x 10 mm 
caplet shaped punches. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evaluation of chewable tablets 
 
Department of Pharmaceutics, Madras Medical College.                                                           Page 68 
 
10. EVALUATION OF CHEWABLE TABLETS  
10.1 Appearance 
   The general appearance of the tablet was studied by the evaluation of the 
parameters like size, colour and odour. 
 Procedure:  10 tablets were visually observed. 
 
 10.2 Thickness68 
 The thickness of the tablet was measured to determine the uniformity of size 
and shape. 
 Procedure: The thickness of the tablet was measured using Vernier caliper. 
 10.3 Friability69 
  Friability of the prepared formulations was determined by using Roche 
friabilator. Pre weighed sample of tablets was placed in the friability tester, which was then 
operated for 100 revolutions, tablets were dedusted and reweighed. The friability of the 
tablets was calculated using the formula mentioned below, 
 
% Friability = Initial weight – Final weight x 100 
                Initial weight  
 
    A friabilator evaluates the ability to withstand mechanical stress 
during packaging, handling and shipping. 
 
  10.4 Hardness70 
 The hardness test was performed to measure the tablet strength. Tablets should be 
hard enough to withstand packaging and shipping but not so hard as to create difficulty 
upon chewing. 
 Procedure: Tablets were taken and its hardness were tested by using               
Dr. Schleuniger Pharmatron model 5Y tablet tester and the readings were noted. 
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10.5 Uniformity of weight71 
  20 tablets were selected randomly and weighed individually and the average 
weight was calculated. Then the individual weight was compared to the average weight. 
Not more than two of the individual weights deviate from the average weight by the 
percentage deviation given below. 
Table No. 15: Average weight and its % deviation allowed 
S.No Average weight of the tablet(mg) Percentage deviation allowed 
1 130 or less 10.0% 
2 More than 130  but less than 324 7.5% 
3 More than 324 5.0% 
 
10.6 Palatability Test72, 73   
  Organoleptic evaluation for the formulated tablets were carried out by the study of 
palatability of tablets. The sweetness, bitterness, mouth feel, aftertaste and flavour 
evaluated as a parameter for the tablets. For this test, 5 healthy volunteers were selected 
and they were asked to chew the tablets in the mouth. Immediately after the evaluation, the 
volunteers were asked to rinse their mouth the volunteers without ingesting the 
disintegrated particles. 
 
 10.7 Disintegration74, 75 
   This test is provided to determine whether tablets disintegrate within the 
prescribed time when placed in a liquid medium at the experimental conditions. Complete 
disintegration is defined as that state in which any residue of the unit except fragments of 
insoluble coating or capsule shell, remaining on the screen of the test apparatus or adhering 
to the lower surface of the disc, if used is a soft mass having no palpably firm core. 
 UNCOATED TABLETS 
  One dosage unit in each of the six tubes of the basket were placed. The 
apparatus was operated using water as the immersion fluid, maintained at 37º ±2ºC. The 
time taken for complete disintegration of tablets was noted. 
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10.8   ASSAY60,76 
   Instrumentation 
 A liquid chromatograph consists of a fixed volume injector loop with a UV-Visible 
Spectrophotometer detector and data management software. 
   Chemicals and Reagents 
• Solvent - a mixture of n-hexane and dehydrated alcohol (5:2). 
• Mobile phase - a filtered and degassed mixture of Acetonitrile, 
Tetrahydrofuran and Water (55:40:5). 
• Water (HPLC grade)     
• Standard preparation - An accurately weighed quantity of USP 
Ubidecarenone RS in the above solvent was taken to get a solution having a 
known concentration of 1.0 mg per mL was prepared. Then a portion of this 
solution was diluted with dehydrated alcohol to obtain a solution having a 
known concentration of about 40 µg per mL. 
• Resolution solution - An accurately weighed quantity of USP 
Ubidecarenone Related Compound A RS in the above solvent was taken to 
get a solution having a concentration of 1.0 mg per mL. Then a portion of 
this solution was diluted with dehydrated alcohol to obtain a solution having 
a concentration of about 40 µg per mL. Mix equal volumes of this solution 
and the Standard preparation. 
• Test  preparation (Assay) 
   20 Tablets were weighed and powdered. An accurately  weighed quantity 
 of the  powder equivalent to about 100 mg of Ubidecarenone was 
transferred to a 100 mL volumetric flask, add 6 mL of Solvent[mixture of n-
hexane and dehydrated alcohol (5:2)] and shaken by mechanical means for 
30 minutes. It was diluted with the solvent mixture upto the volume and 
mixed. It was centrifuged and 1 mL of the supernatant was transferred to a 
25 mL volumetric flask, 2.5 mL of a 0.1% solution of anhydrous ferric 
chloride in alcohol was added, diluted with alcohol to volume and mixed. 
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 Procedure 
  Equal volume (about 15 µL) of the Standard preparation and the Assay preparation 
was injected separately in L1 column. The chromatograms were recorded and the 
responses were measured for the major peaks.  
 The quantity of Ubidecarenone (C59H90O4) was calculated by the formula: 
2500C(rU / rS) 
 Where,  C- Concentration, in mg per mL of USP Ubidecarenone RS in the  
                Standard preparation,   
  rU and rS - Peak responses obtained from the Assay preparation and the Standard    
         preparation, respectively. 
  The System Suitability Parameters 
• The resolution R, between Ubidecarenone and Ubidecarenone related 
compound A - NLT 2.5. 
• The tailing factor - NMT  1.5 
• Relative standard deviation for replicate injections - NMT 2.0%. 
 
10.9 BUFFER PREPARATION DETAILS60 
 Preparation of pH 6.8 Phosphate buffer solution 
  Place 50mL of the monobasic potassium phosphate solution in a 200mL volumetric 
flask and add 22.4mL of 0.2M sodium hydroxide solution then add water to make up 
the volume. 
 Preparation of 0.2M Sodium Hydroxide 
 Dissolve 8g of sodium hydroxide in 1000mL of distilled water. 
 Preparation of 1% Sodium lauryl sulphate 
 Dissolve 1g of sodium lauryl sulphate in 100mL of distilled water. 
 
10.10 DISSOLUTION APPARATUS SPECIFICATIONS77 
 Apparatus  :  Type I (USP) 
 Medium  : Phosphate buffer pH 6.8 
 Volume  : 900ml 
 Speed   : 100rpm 
 Temperature   : 37º C ± 0.5º C 
 Time points  : 10, 20, 30, 40, 50, 60, 75, 90 and 120 minutes. 
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 The amount of Ubidecarenone released was determined by chromatographic 
 technique. 
    Chromatographic specifications60 
 Buffer solution        : Phosphate buffer pH 6.8 
 Mobile Phase       :  Mixture of Methanol and dehydrated alcohol  
 Column        : 5mm x 15cm column that contains packing L1 
 Column temperature   :  35ºC 
 Injection        : 5µl 
 Detection      : Spectrophotometer at 275 nm 
 
 Procedure 
   Equal volumes (about 5 µL) of the Standard preparation and the Assay 
preparation were injected separately into the chromatograph, the chromatograms were 
recorded and responses were measured for the major peaks. The quantity of   
Ubidecarenone in mg was calculated. 
50C (rU / rS) 
Where,  
  C- Concentration in mg per mL of USP Ubidecarenone RS in the Standard 
                    preparation. 
   rU and rS - peak responses obtained from the Assay preparation and the  
        Standard preparation respectively. 
 
10.11 STABILITY STUDY78 
  Tablets were packed in 75 cc Amber Coloured HDPE Bottle with 33 mm 
PP Child Resistant Closure. It was done to generate information regarding the shelf life of 
the formulation and its recommended storage conditions. 
  Accelerated stability test was carried out by keeping the final pack under the 
condition 40±2ºC/75±5%RH and the various parameters such as description, 
disintegration, assay, dissolution and water content were evaluated for the samples 
withdrawn at the time interval of 1st month, 2nd month and 3rd month. 
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11. RESULTS AND DISCUSSION 
11.1 DRUG- EXCIPIENT COMPATIBILITY STUDY 
Table No. 15:  Ubidecarenone – Excipient Compatibility (Initial) 
S. 
No 
Drug-Excipient Ratio 
Initial 
Appearance Assay 
(%) 
Water 
Content(%) 
1 UB – Pearlitol Flash  1:0.5 98.0 3.38 Yellowish white powder 
2 UB – Crospovidone 1:0.25 97.0 3.95 White to off white powder 
3 UB – Poloxamer 407 1:0.25 99.0 1.97 Orange yellowish powder 
4 UB – Aspartame 1:0.25 97.0 4.12 Orange yellowish powder 
5 UB–Saccharin Sodium 1:0.25 96.0 4.98 Orange yellowish powder 
6 UB – Mint Flavour 1:0.25 98.0 3.67 Orange yellowish powder 
7 UB – Orange Flavour 1:0.25 99.0 3.83 Orange yellowish powder 
8 
UB–Colloidal Silicon 
Dioxide 
1:0.25 98.0 3.72 Yellow whitish powder 
9 
UB–Sodium Stearyl 
Fumarate 
1:0.25 97.0 2.12 Orange yellowish powder 
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Table No. 16:  Ubidecarenone – Excipient Compatibility (Accelerated Stability Study) 
S. 
No Drug-Excipient Ratio 
40°C/ 
75%RH-2nd 
week 
Appea 
rance 
40°C/ 
75%RH-4th Week 
Appea 
rance Assay 
(%) 
Water 
Content
(%) 
Assay 
(%) 
Water 
content 
(%) 
1 UB – Pearlitol Flash 1:0.5 96.12 3.28 NC 96.87 3.23 NC 
2 UB – Crospovidone 1:0.25 95.84 3.81 NC 95.62 3.61 NC 
3 UB – Poloxamer 407 1:0.25 97.65 1.90 NC 97.54 1.75 NC 
4 UB – Aspartame 1:0.25 95.84 4.06 NC 95.61 4.46 NC 
5 UB – Saccharin 
Sodium 
1:0.25 94.64 4.89 NC 94.91 4.43 NC 
6 UB – Mint Flavour 1:0.25 97.58 3.59 NC 97.64 3.72 NC 
7 UB – Orange 
Flavour 
1:0.25 96.72 3.78 NC 96.98 3.84 NC 
8 UB – Colloidal 
Silicon Dioxide 
1:0.25 95.64 3.67 NC 95.35 3.24 NC 
9 UB – Sodium 
Stearyl Fumarate 
1:0.25 95.67 1.99 NC 95.64 1.62 NC 
UB- Ubidecarenone, NC -   No change. 
Inference  
 From the above results  
 It was found the drug content was within the limits. 
 No change in physical appearance. 
Thus it was found that all the excipients were compatible with drug. 
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11.2 API CHARACTERIZATION 
 Ubidecarenone raw material was analyzed for the parameters like particle size 
distribution, derived properties like bulk density, tapped density, Compressibility Index, 
Hausner’s ratio and Angle of Repose. 
 Particle size distribution of Ubidecarenone 
Table No. 17: Particle size distribution of Ubidecarenone 
S.No ASTM 
Sieve 
No. 
Empty 
Sieve 
weight 
(g) 
Weight of 
Sieve + 
sample 
retained (g) 
Weight of 
sample 
retained (g) 
% Sample 
retained 
Cumulative % 
retained 
1 20 364 366.5 2.5 12.5 12.5 
2 40 363 367.5 4.5 22.5 35.0 
3 60 341.5 345 3.5 17.5 52.5 
4 80 336 337.5 1.5 7.5 60.0 
5 100 331.5 333 1.5 7.5 67.5 
6 140 333 334.5 1.5 7.5 75.0 
7 200 307 310.5 3.5 17.5 92.5 
8 Pan 498.5 500 1.5 7.5 100 
 
From the above table it is clear that maximum particles were retained on sieve No. 40.  
 
 Derived properties of Ubidecarenone  
 
                        Table No. 18: Derived properties of Drug 
 
Bulk density (g/mL)  0.446 
Tapped density  (g/mL)  0.657 
Compressibility index (%) 32.14  
Hausner’s Ratio 1.47 
Angle of Repose (θ)  37 º 48’ 
 
 The Ubidecarenone raw material had very poor flow property. Therefore the drug was 
blended with the excipients to improve the flow property. 
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11.3 Formulation Trials for optimizing concentration of Flavours 
 In these trials, concentration of mint flavour and orange flavour were varied, keeping 
concentration of all the other ingredients as constant and Four trials (AI, AII, AIII, A IV) were 
formulated  and the concentration of flavouring agents was optimized based on evaluation 
by  volunteers. 
                                  Table No. 19:  Flavour Assessment 72 
Flavour score Report 
0-2 Poor 
3 Average 
4 Acceptable 
5 Good 
 
Table No. 20: Evaluation of Flavour by Volunteers 
  Flavour score 
Volunteer A I A II A III A IV 
I 2 3 4 5 
II 1 3 4 5 
III 1 3 4 5 
IV 1 3 4 5 
V 1 3 4 5 
 
Flavour was evaluated by human healthy volunteers. Five volunteers were involved in 
evaluating the flavour and the score for flavour is given in the range of 0-5. 
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Fig 4: Comparison of Flavours in Formulation A I – A IV 
 
Inference  
 Formulation A IV was selected as it had good flavour by the reports from the 
volunteers and thus concentration of  Orange flavour (0.21%) and Mint flavour (0.83%) were 
optimized. 
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11.4 Formulation Trials for optimizing concentration of Sweeteners 
   In these trials, concentration of sweetening agents were varied, keeping 
concentration of all the other ingredients constant and Four trials (B I, B II, B III, B IV) were 
formulated and the concentration of sweetening agents was optimized based on evaluation by 
volunteers. 
 
     Table No. 21:  Taste Assessment 72 
 
Sweet score Report 
0-2 Poor 
3 Average 
4 Acceptable 
5 Good 
 
Table no. 22: Evaluation of Taste by Volunteers 
 
 Sweet score 
Volunteer B I B II B III B IV 
I 1 3 4 5 
II 1 3 4 5 
III 1 3 4 5 
IV 1 3 4 5 
V 2 3 4 5 
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Fig 5: Comparison of Sweetening Agents in Formulation B I - BIV 
 
Inference 
     Formulation B IV was selected, as it had Good taste by the reports from the 
volunteers and thus the concentration of sweetening agents Aspartame (1.6%) and Sodium 
Saccharin (0.4%) were optimized. 
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11.5 Formulation Trials for optimizing concentration of Disintegrant 
 In these trials, concentration of Crospovidone was varied, keeping concentration of all 
the other ingredients as constant and Four trials (C I, C II, C III, C IV) were formulated and 
the concentration of disintegrating agent was optimized based on disintegration time of 
tablets. 
 
Table No. 23: Comparison of Disintegration time for formulations (C I – C IV) 
Disintegration time (min)* 
C I C II C III C IV 
9’ 47” ±0.8695  5’ 10” ±0.6082 1’ 22” ±0.1408 1’ 47” ±0.3209 
* Mean ± SD (n=6) 
 
 
Fig 6: Comparison of disintegration time for formulations C I – C IV 
 
 
Inference 
 The Formulation C III was found to have faster disintegration compared to other three 
formulations. Thus the formulation C III containing 5% of Crospovidone was optimized. 
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11.6 Formulation Trials for optimizing concentration of Wetting Agent 
In these trials, concentration of Poloxamer 407 was varied, keeping concentration of 
all the other ingredients as constant and Four trials (D I, D II, D III, D IV) were formulated 
and the concentration of wetting agent was optimized based on dissolution profile of tablets. 
 
Table No. 24:  In vitro drug release for the batches D I – D IV 
Time 
(Min) Cumulative % Drug Release
 
*
 
 D I D II D III D IV 
10 18.66 ±0.6437 24.76 ±0.5936 30.81 ±0.2693 37.33 ±0.5368 
20 29.72 ±0.5118 41.47 ±0.6810 55.13 ±0.7435 58.72 ±0.5204 
30 33.75 ±0.4235 61.21 ±0.5449 75.38 ±0.5602 77.74 ±0.7184 
45 42.35 ±0.2286 71.39 ±0.5610 85.41 ±0.4077 88.25 ±0.1662 
60 54.88 ±0.4194 82.45 ±0.5246 95.33 ±0.3454 98.91 ±0.3802 
75 61.43 ±0.7650 90.78 ±0.7457 97.59 ±0.8941 99.60 ±0.0854 
90 80.88 ±0.6077 98.32 ±0.2938 99.40 ±0.1845 99.80 ±0.0681 
120 89.17 ±0.4712 98.66 ±0.2307 99.60 ±0.2168 98.43 ±0.0854 
*
 Mean ± S.D (n = 6) 
    USP limits: Q value not less than 75% at the end of 45 minutes 2  
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Fig 7: Comparison of dissolution profile for Formulations D I – D IV 
 
 Inference  
  Formulations D III and D IV having Poloxamer 407 concentration (0.83%) 
and (1.25%) resulted in 85.41% and 88% of drug release respectively at the end of 45 
minutes. The formulation D III had desired release (Q value not less than 75%). Thus 
formulation D III having 0.83% of Poloxamer 407 was optimized. 
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11.7 Formulation Trials for optimizing concentration of Glidant &    
         Lubricant  
 In these trials, concentration of Colloidal silicon dioxide (Glidant) and Sodium stearyl 
fumarate (Lubricant) were varied, keeping concentration of all the other ingredients as 
constant and Four trials (E I, E II, E III, E IV) were formulated and various physical 
characteristics such as sticking, picking and striation were investigated. 
 
Table No. 25: Post Compression Evaluation of Defects in Tablets for Formulations  
(EI – EIV) 
S.No Parameter E I E II E III E IV 
1 Picking     
2 Sticking     
3 Striation     
4 Remarks No defect  No defect  No defect  No defect  
 - Present    - Absent 
 
Inference 
 All the Formulations E I to E IV were found to be free from sticking, picking and 
striation. The Formulation E III having low concentration of Colloidal silicon dioxide (0.5%) 
and Sodium stearyl fumarate (0.5%) was optimized. 
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11.8 FINALIZED FORMULATION (E III) AND ITS CHARACTERIZATION 
 
                      Table No. 26: Ingredients of the Optimized Batch (E III) 
S.No Ingredients mg / tablet 
1 Ubidecarenone 400.00 
2 Pearlitol Flash 680.50 
3 Crospovidone 60.00 
4 Poloxamer 407 10.00 
5 Aspartame 20.00 
6 Saccharin Sodium 5.00 
7 Mint Flavour 2.50 
8 Orange Flavour 10.00 
9 Colloidal silicon dioxide 6.00 
10 Sodium stearyl fumarate 6.00 
Total 1200.00 
 
 
 
Table No. 27: Pre Compression Parameters of Optimized Batch (E III) 
S.No Parameter  E III batch  
1  Bulk Density (g/mL)* 0.4732 ± 0.0157 
2 Tapped Density (g/mL)* 0.6121 ± 0.0017 
3 Compressibility Index (%)* 22.70 ± 2.719 
4  Hausner’s Ratio * 1.30 ± 0.0462 
5 Angle of Repose (θ) 32.20 
* Mean ±SD (n=3) 
 
 The flow property of blend is graded as “good” based on Angle of repose 
value. 
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   Table No. 28: Post compression parameters of Optimized Batch (E III) 
Parameter  E III batch 
Uniformity of weight (g)***  1.204 ±0.0021 
Thickness (mm)* 4.57 ±0.0440 
Hardness (kp)* 11.0 ±0.3162 
Friability (%) 0.394 
Disintegration Time (min)** 1’ 46” ±0.0732 
Assay (%) 98.14 
* Mean ±SD (n=5), **Mean ±SD (n=6), ***Mean ±SD (n=20) 
 
The formulated tablets were found to be  
 Uniform in weight. 
 Uniform in thickness. 
 Friability was within the limits. 
 Disintegration time was within the limits. 
 Drug content by assay complies with USP limits. 
 
    Table No. 29: Palatability test for Optimized Formulation (E III) 
Volunteer 
Sweet score Flavour score 
E III E III 
I 5 5 
II 5 5 
III 5 5 
IV 5 5 
V 5 4 
Report Good Good 
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Fig 8: Palatability test for Optimized batch (E III) 
 
  The sweet and flavour for the optimized batch was found to be good based on 
reports by the volunteers. 
Table No. 30: In vitro release study for the Optimized batch (E III) 
Parameter E III batch 
Dissolution 
USP-I (Basket), 100 rpm, 900 ml,  
pH 6.8 Phosphate buffer + 1% SLS. 
Time (min)  Cumulative % Drug Release* 
10 37.19 ± 0.3894 
20 58.88 ± 0.1930 
30 77.54 ± 0.9681 
45 88.65 ± 0.3530 
60 98.85 ± 0.4619 
75 99.40 ±0.1401 
90 99.52 ±0.2309 
120 98.51 ± 0.0513 
* Mean ±SD (n=6) 
  The in vitro drug release of the optimized batch was found to be 88.65% at the 
end of 45 minutes and 99.52% at the end of 90 minutes. 
 
No. of volunteers 
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Fig 9: In vitro drug release for Optimized formulation (E III) 
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11.9 STABILITY STUDIES 
 Pack 
 75cc Amber Coloured  HDPE Bottle with 33 mm PP Child Resistant Closure with 
Induction Seal  Liner With 1 g per bottle of 6 g/yard Cotton as dunnage and 2 numbers of 1 g 
Silica gel canister as  desiccant. 
Count: 30 Tablets / bottle 
  
Table No. 31: Stability study of Optimized Formulation (E III) 
 
S. 
No 
Parameters Initial 1st month 2nd month 3rd month 
1 Description 
White to off-
white shaped  
tablets 
White to off-
white shaped  
tablets 
White to off-
white shaped  
tablets 
White to off-
white shaped  
tablets 
2 
Uniformity of  
weight(g) * 
1.204 ± 
0.0021 
1.203 ± 
0.0021 
1.203 ± 
0.0025 
1.202 ± 
0.0027 
3 Thickness(mm)**   
4.57 ± 
0.0440 
4.57 ± 
0.0150 
4.56 ± 
0.0172 
4.55 ± 
0.0160 
4 Hardness(Kp)** 
11.0 ± 
0.3162 
11.12 ± 
0.2315 
11.08 ± 
0.1939 
11.08 ± 
0.2400 
5 Friability (%) 0.367 0.393 0.390 0.403 
6 
Disintegration 
time (min) *** 
1’ 52” ± 
0.0732 
1’ 47” ± 
0.0654 
1’ 43” ± 
0.0528 
1’ 45” ± 
0.0802 
7 
 
Water content by 
KF 
 
4.35%  w/w 4.51% w/w 4.56% w/w 4.57% w/w 
* Mean ±SD (n=20), ** Mean ±SD (n=5), *** Mean ±SD (n=6) 
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Table No. 32: Assay and Dissolution Profile of Formulated Ubidecarenone 
Chewable Tablets 
 
Time interval 
Drug  
Content (%) 
%  Drug release at the 
    end of 45 minutes * 
Initial 98.14 88.65 ±0.3530 
1st  month 98.45 88.77 ±0.2082 
2nd  month 97.86 88.77 ± 0.2495 
3rd month 98.54 88.45 ±0.2732 
                                                * Mean ±SD (n=6) 
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12. SUMMARY AND CONCLUSION 
 
 The aim of the present study was to formulate Ubidecarenone chewable tablets and 
was achieved. 
 Ubidecarenone raw material had poor flow characteristics. Hence, it was blended 
using directly compressible excipients which improve the flow property of the blend 
and chewable tablets were formulated by direct compression. 
 The excipients used in the formulation were subjected to Drug- Excipient 
compatibility study and found that the excipients were compatible with the drug. 
 Optimization study for flavouring agent was conducted and found that the 
Combination of Orange flavour (0.83%) and Mint flavour (0.21%) were found to be 
palatable. 
 Optimization study for sweetening agent was conducted and as a result 1.66% of 
Aspartame and 0.42% of Saccharin Sodium were optimized and it was used to get 
good sweet taste. 
 5% of Crospovidone (Polyplasdone XL 10) was optimized to get a rapid 
disintegration of tablets. 
 Poloxamer 407 (Lutrol Micro 127 in 0.83%) produced a drug release of 88.25% at the 
end of 45 minutes and it complies with USP limits. Thus it was optimized as good 
wetting agent. 
 Colloidal Silicon Dioxide (Cabosil in 0.5%) and Sodium Stearyl Fumarate (Pruv in 
0.5%) were optimized as the glidant and lubricant to produce tablets without sticking, 
picking and striation. 
 The optimized formulation blend has a good flow property based on its angle of 
repose value. 
  The optimized formulation blend (E III) was compressed by direct compression 
technique in 16 station tablet compression machine using 21 x 10 mm caplet shaped 
punches. 
 The formulated chewable tablets were evaluated for post compression parameters and 
found that they were uniform in weight, thickness and hardness. The friability was 
within the limits.  
 The disintegration time of chewable tablets for finalized batch (E III) was 1 minute 45 
seconds.  
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 The drug content of the chewable tablets was 98.14% and is within the USP limits 
(90-110%). 
 Drug release of 88.25% was observed at the end of 45 minutes and 99.75% at the end 
of 90 minutes for optimized batch (E III) and it was within the USP limits.  
 The formulated chewable tablets were subjected to accelerated stability studies and 
the tablets were found to be stable. 
 The Ubidecarenone in the form of chewable tablets (400mg) will improve the 
compliance of Parkinsonism patients. 
 
 Future plan  
 The scale up studies is required for the optimized formulation to meet the Industrial 
requirements. 
 The bioequivalence studies in human volunteers should be conducted to know the 
 in vivo performance and efficacy of the formulation. 
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